[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1689
1. Manabe T, Hirose Y, Kiryuu T, Koudo H, Hoshi H: Magnetic resonance imaging of endometrial cancer and clear cell cancer. J Comput Assist Tomogr; 2007 Mar-Apr;31(2):229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of endometrial cancer and clear cell cancer.
  • OBJECTIVE: We attempt to clarify specific imaging findings useful for differential diagnosis between endometrioid cancer and clear cell cancer.
  • METHODS: We examined magnetic resonance imaging features on 11 endometrioid cancer and 9 clear cell cancer patients.
  • RESULTS: Endometrioid cancer had a predominantly multilocular appearance, but clear cell cancer showed almost equally multilocular and unilocular appearances.
  • For the growth pattern, endometrioid cancer in 6 patients demonstrated a "centric pattern" and an "eccentric pattern" in 4, whereas clear cell cancer showed predominantly an eccentric pattern.
  • An internal slit in the solid component was seen in 4 endometrioid cancer patients but not seen in any of the patients with clear cell cancer.
  • CONCLUSIONS: The magnetic resonance imaging appearance of the internal slit in solid components and the presence of endometrial disease are key factors in differentiating endometrioid cancer from clear cell cancer, although lesion locularity and growth pattern are not specific in both.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media / administration & dosage. Diagnosis, Differential. Endometrium / pathology. Female. Humans. Image Enhancement / methods. Middle Aged. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414759.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


2. Amarapurkar AD, Rege JD, Joshi AS, Vaiphei K, Amarapurkar DN: Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors. Indian J Pathol Microbiol; 2006 Jul;49(3):341-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of hepatocellular carcinoma (HCC) is not always easy on simple hematoxylin and eosin (H&E) stain.
  • The diagnostic problems arise when tumor shows pseudoglandular, pleomorphic or clear cell differentiation.
  • Slides were examined by experienced pathologist without any information of clinical or H&E diagnosis.
  • Subsequently immunohistochemistry results were correlated with histology and clinical diagnosis.
  • On correlating with H&E sections, out of 26 positive cases, 25 (89.2%) were HCC and one was the case of metastasis of mucin secreting adenocarcinoma.
  • From 36 tumors with negative staining 3 were cases of HCC, 27 metastatic adenocarcinomas and 6 cholangiocarcinomas.
  • Only one case of liver metastasis of mucin secreting adenocarcinoma showed positivity.
  • [MeSH-major] Antibodies, Monoclonal. Antibodies, Neoplasm / immunology. Biomarkers, Tumor. Carcinoma, Hepatocellular / pathology. Hepatocytes / immunology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / immunology. Antigens, Surface / immunology. Biopsy. Cell Differentiation / immunology. Diagnosis, Differential. Humans. Immunohistochemistry. Liver / metabolism. Liver / pathology. Neoplasm Metastasis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001880.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst; 2006 Mar 1;98(5):303-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
  • BACKGROUND: Most cancers of the uterine cervix are squamous cell carcinomas.
  • Although the incidence of such carcinomas of the uterine cervix has declined over time, that of cervical adenocarcinoma has risen in recent years.
  • A total of 167 case patients with invasive cervical adenocarcinoma (112 with adenocarcinoma and 55 with adenosquamous carcinoma) and 1881 hospital-based control subjects were included.
  • HPV DNA was analyzed in cervical specimens with the GP5+/6+ general primer system followed by type-specific hybridization for 33 HPV genotypes.
  • RESULTS: The adjusted overall odds ratio for cervical adenocarcinoma in HPV-positive women compared with HPV-negative women was 81.3 (95% CI = 42.0 to 157.1).
  • Cofactors that showed clear statistically significant positive associations with cervical adenocarcinoma overall and among HPV-positive women included never schooling, poor hygiene, sexual behavior-related variables, long-term use of hormonal contraception, high parity, and HSV-2 seropositivity.
  • Parity had a weaker association with adenocarcinoma and only among HPV-positive women.
  • Use of an intrauterine device (IUD) had a statistically significant inverse association with risk of adenocarcinoma (for ever use of an IUD compared with never use, OR = .41 [95% CI = 0.18 to 0.93]).
  • Smoking and chlamydial seropositivity were not associated with disease.
  • CONCLUSIONS: HPV appears to be the key risk factor for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenocarcinoma / virology. Mass Screening. Papillomaviridae. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / prevention & control. Uterine Cervical Neoplasms / virology. Viral Vaccines / therapeutic use
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / prevention & control. Carcinoma, Squamous Cell / virology. Case-Control Studies. Female. Humans. Logistic Models. Middle Aged. Multicenter Studies as Topic. Multivariate Analysis. Odds Ratio. Prevalence. Primary Prevention. Risk Factors


Advertisement
4. Ahrens WA, Barrón-Rodriguez LP, McKee M, Rivkees S, Reyes-Múgica M: Clear cell adenocarcinoma of the cervix in a child without in utero exposure to diethylstilbestrol: a case report and review of the literature. Pediatr Dev Pathol; 2005 Nov-Dec;8(6):690-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the cervix in a child without in utero exposure to diethylstilbestrol: a case report and review of the literature.
  • Histologic analysis revealed a clear cell adenocarcinoma.
  • Clear cell adenocarcinoma is an extremely rare neoplasm that should be kept in the differential diagnosis of cervicovaginal lesions in children, even in the absence of a clinical history of in utero diethylstilbestrol exposure.
  • [MeSH-major] Adenocarcinoma / pathology. Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Pregnancy. Prenatal Exposure Delayed Effects. Rhabdomyosarcoma, Embryonal / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222478.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


5. Ivanov SV, Ivanova AV, Salnikow K, Timofeeva O, Subramaniam M, Lerman MI: Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun; 2008 Jun 13;370(4):536-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.
  • The inability of the mutant VHL protein to destabilize HIF-1 plays a crucial role in malignant angiogenesis.
  • We used expression arrays and cell lines with different VHL status to identify ECM-associated genes controlled by VHL.
  • Analyzing the mechanism of TGFBI up-regulation in clear cell carcinoma, we identified a novel VHL target, a Kruppel-like transcriptional factor 10 (KLF10).

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):865-74 [11154273.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Mar;232(3):344-52 [17327467.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15306-15 [11278694.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4184-9 [11358843.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6996-7001 [11585723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2848-53 [11880636.001]
  • [Cites] Jpn J Clin Oncol. 2002 Mar;32(3):85-9 [11956302.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2929-36 [12019174.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3803-11 [12097293.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28003-9 [12034705.001]
  • [Cites] Oncogene. 2002 Aug 22;21(37):5783-90 [12173049.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):461-8 [17624412.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):539-48 [17729309.001]
  • [Cites] J Pathol. 2008 Jan;214(1):46-57 [17973242.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 9;1588(1):1-6 [12379307.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46159-65 [12270930.001]
  • [Cites] Neurosci Lett. 2003 Jan 16;336(2):93-6 [12499048.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):213-26 [12510773.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):551-60 [12579308.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2045-53 [12673209.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2973-9 [12824240.001]
  • [Cites] FEBS Lett. 2004 Jan 2;556(1-3):137-42 [14706840.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1235-43 [15026807.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Apr 15;196(2):258-65 [15081272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 25;101(21):8132-7 [15141079.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26948-58 [15087465.001]
  • [Cites] Exp Mol Med. 2004 Jun 30;36(3):211-9 [15272232.001]
  • [Cites] DNA Cell Biol. 1992 Sep;11(7):511-22 [1388724.001]
  • [Cites] Nucleic Acids Res. 1995 Dec 11;23(23):4907-12 [8532536.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 11;1395(3):288-92 [9512662.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):25929-36 [9748269.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):5902-12 [10454537.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4440-5 [10485495.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] Mol Carcinog. 2006 Feb;45(2):84-92 [16329146.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):574-84 [16436671.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2818-26 [16314830.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5314-21 [16707457.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):615-25 [16683255.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6928-35 [16849536.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):802-12 [16878149.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • (PMID = 18359287.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 BC008579-14; United States / NCI NIH HHS / CO / N01-CO-56000
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Early Growth Response Transcription Factors; 0 / Extracellular Matrix Proteins; 0 / KLF10 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Transforming Growth Factor beta; 148710-76-3 / betaIG-H3 protein; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS51643; NLM/ PMC2413015
  •  go-up   go-down


6. Stefănescu BI: [Adenocarcinoma of the uterine cervix--risk factors]. Rev Med Chir Soc Med Nat Iasi; 2007 Jan-Mar;111(1):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the uterine cervix--risk factors].
  • [Transliterated title] Adenocarcinomul colului uterin--factori de risc.
  • Adenocarcinoma is the second most common malignancy of the uterine cervix following squamous cell carcinoma.
  • The incidence of adenocarcinomas has been increasing, both in absolute numbers and in proportion to squamous carcinomas.
  • It is not very clear whether risk factors identified in squamous cell carcinoma of the cervix are shared by cervical adenocarcinoma as well.
  • While infection with the human papillomavirus appears to be the most important cause of both histologic types of cervical cancer, there has been found differences between adenocarcinoma and squamous cell carcinoma regarding the importance of other risk factors such as reproductive history and smoking.
  • [MeSH-major] Adenocarcinoma / etiology. Uterine Cervical Neoplasms / etiology
  • [MeSH-minor] Carcinoma, Squamous Cell / etiology. Contraceptive Agents / adverse effects. Female. Humans. Obesity / complications. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Risk Factors. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595861.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Contraceptive Agents
  • [Number-of-references] 33
  •  go-up   go-down


7. Chi DS, Barlin JN, Ramirez PT, Levenback CF, Mironov S, Sarasohn DM, Iyer RB, Dao F, Hricak H, Barakat RR: Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller. Int J Gynecol Cancer; 2010 Apr;20(3):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller.
  • INTRODUCTION: We previously reported a 52% correlation between the primary surgeon's assessment and the postoperative computed tomographic (CT) scan findings of residual disease in patients reported to have undergone cytoreduction to residual disease of 1 cm or smaller.
  • METHODS: Patients scheduled for primary cytoreductive surgery for presumed advanced ovarian carcinoma were offered enrollment in a prospective study evaluating the ability of preoperative CT scan to predict cytoreductive outcome.
  • If cytoreduction to residual disease of 1 cm or smaller was reported, a CT scan was done 7 to 35 days postoperatively.
  • The CT scan findings were graded by protocol radiologists using a qualitative analysis scale from 1 (normal) to 5 (definitely malignant).
  • Postoperative CT scans confirmed the primary surgeon's assessment of no residual disease larger than 1 cm in 38 cases (57%).
  • In 29 cases (43%), the radiologist found residual disease larger than 1 cm and reported it as probably or definitely malignant.
  • Age (P = 0.040), stage (P = 0.038), and residual disease of 0.5 mm or smaller versus 0.6 to 1.0 cm (P = 0.018) were significant for overall survival on multivariate analysis.
  • CONCLUSIONS: On this follow-up analysis, only age, stage, and residual disease were significant prognostic factors for overall survival.
  • Discordant findings between the primary surgeon's assessment and the postoperative CT scan findings of residual disease was not an independent prognostic factor.
  • [MeSH-major] Cystadenocarcinoma, Serous / surgery. Fallopian Tube Neoplasms / diagnosis. Neoplasm, Residual / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Postoperative Care. Prognosis. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375796.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Tillou X, Demailly M, Hakami F, Westeel PF, Saint F, Petit J: De novo renal carcinoma in renal transplant recipients: effect of early treatment. Transplant Proc; 2009 Oct;41(8):3314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo renal carcinoma in renal transplant recipients: effect of early treatment.
  • OBJECTIVE: To evaluate the epidemiology, diagnosis, and outcome of de novo renal cell carcinoma in renal transplant recipients.
  • Incidence, diagnosis, histologic type, treatment, and outcome were analyzed in all patients.
  • RESULTS: Thirty-three patients underwent nephrectomy because of suspect renal lesions including 22 de novo tumors in 21 native kidneys (renal clear-cell carcinoma in 15 and papillary carcinoma in 7).
  • Mean (range) time after diagnosis was 25.6 (2.3-105.5) months.
  • Only 1 patient died, at 8 months after diagnosis.
  • In our patients, 65% of patients had malignant lesions.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology. Kidney Neoplasms / epidemiology. Kidney Transplantation / adverse effects
  • [MeSH-minor] Abdomen / ultrasonography. Adult. Aged. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Humans. Incidence. Middle Aged. Nephrectomy. Prognosis. Retrospective Studies. Risk Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19857739.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Uzochukwu NO, Shrier DA, Lapoint RJ: Clear cell carcinoma of the base of the tongue: MR imaging findings. AJNR Am J Neuroradiol; 2007 Jan;28(1):127-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the base of the tongue: MR imaging findings.
  • Clear cell carcinoma of the base of the tongue is a rare minor salivary gland neoplasm, and to our knowledge, the MR imaging appearance of this entity has not been described.
  • We present the MR imaging findings in such a case and review the differential diagnosis for tongue base masses in an adult.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Magnetic Resonance Imaging. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Deglutition Disorders / etiology. Diagnosis, Differential. Female. Humans. Laryngoscopy. Middle Aged. Tongue / pathology. Tongue / surgery

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213438.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kato N, Takeda J, Fukase M, Motoyama T: Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol; 2010 Jun;23(6):881-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling.
  • The stroma in ovarian clear cell carcinoma often shows alternate mucoid and hyalinized change.
  • We examined 60 ovarian clear cell carcinomas for the distribution and nature of the mucoid stroma.
  • Twenty-nine of 60 (48%) clear cell carcinomas showed a mucoid stroma, either focally (21 cases) or diffusely (8 cases).
  • The mucoid stroma in clear cell carcinomas was distinct from that in other surface epithelial tumors as follows: it showed a compact spherule-like appearance, commonly occupying the cores of small papillae.
  • It also exhibited a cribriform pattern, resembling that of adenoid cystic carcinoma.
  • Among 40 clear cell carcinomas that had at least one type of stroma, 26 (65%) had both, either concomitantly or separately.
  • In vitro, a clear cell carcinoma cell line, HAC-2, formed a spherule-like structure containing hyaluronan in the center, and a significant amount of hyaluronan was detected by latex agglutination immunoturbidimetry, indicating that HAC-2 itself has the potential to produce hyaluronan.
  • All of these facts indicate that the spherule-like mucoid stroma and hyalinized stroma represent different phases of the stromal remodeling process, which is promoted by the deposition of different extracellular matrices produced by clear cell carcinoma cells.
  • The spherule-like mucoid stroma and hyalinized stroma are considered complementary diagnostic signatures of ovarian clear cell carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Extracellular Matrix / metabolism. Hyaluronic Acid / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Animals. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305617.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


11. Kim A, Serada S, Enomoto T, Naka T: Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Expert Opin Ther Targets; 2010 Sep;14(9):963-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
  • Among the four major histological subtypes of EOC, clear cell carcinoma (CCC) of the ovary is highly resistant to platinum-based chemotherapy and is consequently associated with poor patient prognosis in advanced stages.
  • TAKE HOME MESSAGE: Annexin A4 enhances cancer cell chemoresistance and is overexpressed in tumors of patients with ovarian CCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Annexin A4 / metabolism. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Disease Progression. Drug Delivery Systems. Drug Resistance, Neoplasm. Female. Gene Expression Regulation, Neoplastic. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673185.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A4; 0 / Antineoplastic Agents
  •  go-up   go-down


12. Vera-Alvarez J, García-Prats MD, Marigil-Gómez M, Abascal-Agorreta M, López-López JI, Ramón-Cajal JM: Clear cell carcinoma of the ovary diagnosed in ascitic fluid. A case report. Acta Cytol; 2007 Jan-Feb;51(1):107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the ovary diagnosed in ascitic fluid. A case report.
  • BACKGROUND: Clear cell carcinoma of the ovary (CCC) is a rare variety of ovarian cancer.
  • Peritoneal fluid cytology revealed papillary clusters of cells with clear cytoplasm and extracellular hyaline material generally without neoplastic cells.
  • The tumor was excised, and the histologic sections confirmed the cytologic diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Ascites / etiology. Ascites / pathology. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328509.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Thompson RH, Dong H, Kwon ED: Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res; 2007 Jan 15;13(2 Pt 2):709s-715s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
  • B7-H1 encompasses a recently discovered cell surface glycoprotein within the B7 family of T-cell co-regulatory molecules.
  • Tumor-associated B7-H1, as well as B7-H1 on activated lymphocytes, has been shown to impair antigen-specific T-cell function and survival in vitro.
  • Our group has recently reported that B7-H1 is aberrantly expressed in both primary and metastatic renal cell carcinoma (RCC) as revealed via immunohistochemical staining of both fresh-frozen and paraffin-embedded nephrectomy specimens.
  • In addition, we have shown that B7-H1 expression by clear cell RCC tumors (or infiltrating mononuclear cells) correlates with aggressive pathologic features, including advanced tumor-node-metastasis stage, tumor size, higher nuclear grade, and coagulative necrosis.
  • In one study of 306 patients, with a median clinical follow-up of 11 years, we reported that RCC B7-H1 expression correlates with increased risk of disease progression, cancer-specific death, and overall mortality even after multivariate adjustment.
  • Such associations may relate to the recognized ability of B7-H1 to inhibit T-cell-mediated antitumoral immunity.
  • [MeSH-minor] Animals. Antigens, CD274. Antigens, Neoplasm / metabolism. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Disease Models, Animal. Humans. Immunotherapy / methods. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Mice. Neoplasm Metastasis. Prognosis. T-Lymphocytes / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255298.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Antigens, Neoplasm; 0 / CD274 protein, human
  • [Number-of-references] 42
  •  go-up   go-down


14. Zell JA, Iyer PR, Kukes GD, Beamon DB: An unusual case of renal carcinoma. Pathology; 2006 Aug;38(4):370-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of renal carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Kidney Neoplasms / pathology. Pleural Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916734.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


15. Yokota N, Koizume S, Miyagi E, Hirahara F, Nakamura Y, Kikuchi K, Ruf W, Sakuma Y, Tsuchiya E, Miyagi Y: Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer; 2009 Dec 15;101(12):2023-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Ectopic fVII expression occurs frequently in ovarian cancers, particularly in clear cell carcinoma.
  • We further showed that ovarian cancer cells express TF-fVIIa on the cell surface under normoxia and that this procoagulant activity is enhanced by hypoxic stimuli.
  • CONCLUSION: These results raise the possibility that cancer cell-derived TF-fVIIa could cause thrombotic events in ovarian cancer patients.
  • [MeSH-minor] Cell Hypoxia. Cell Line, Tumor. Cell-Derived Microparticles / secretion. Female. Humans. Neoplasms, Glandular and Epithelial / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Res. 2007;120 Suppl 2:S7-12 [18023716.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1053-7 [17895896.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jun 27;371(2):251-5 [18423372.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):425-37 [18500244.001]
  • [Cites] J Thromb Haemost. 2008 Sep;6(9):1517-24 [18433463.001]
  • [Cites] Pathophysiol Haemost Thromb. 2008;36(3-4):177-83 [19176990.001]
  • [Cites] Cell. 1988 May 20;53(4):505-18 [3286010.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1567-76 [8623925.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8298-303 [9653181.001]
  • [Cites] Thromb Haemost. 1998 Oct;80(4):598-602 [9798977.001]
  • [Cites] J Thromb Haemost. 2004 Nov;2(11):2065-7 [15550054.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] J Thromb Haemost. 2005 Aug;3(8):1737-44 [16102040.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):119-25 [15990161.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):755-61 [16380413.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7067-74 [16849552.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7983-90 [16912173.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9453-60 [17018600.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):70-6 [17194906.001]
  • [Cites] Thromb Haemost. 2007 Jan;97(1):119-23 [17200778.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):290-5 [17211468.001]
  • [Cites] J Thromb Haemost. 2007 Mar;5(3):520-7 [17166244.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):480-7 [10690527.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2870-5 [17504985.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):784-90 [17408726.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1723-9 [17496204.001]
  • [Cites] J Thromb Haemost. 2008 May;6(5):781-8 [18284604.001]
  • (PMID = 19904262.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL060742
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9001-25-6 / Factor VII; 9035-58-9 / Thromboplastin
  • [Other-IDs] NLM/ PMC2795428
  •  go-up   go-down


16. Larré S, Kanso C, De La Taille A, Hoznek A, Vordos D, Yiou R, Abbou CC, Salomon L: Retroperitoneal laparoscopic radical nephrectomy: intermediate oncological results. World J Urol; 2008 Dec;26(6):611-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From 1995 to 2006, 146 consecutive patients with removal of a malignant kidney tumor by laparoscopic retroperitoneal radical nephrectomy were analysed retrospectively.
  • Disease-free survival and specific survival were determined among patients free of metastasis at surgery.
  • The pathology of these cancers were: 108 clear cell carcinomas, 26 papillary carcinomas, 10 chromophobe carcinomas, and 2 miscellaneous.
  • Five patients had metastatic disease at presentation.
  • The disease-free survival at 5 and 10 years, were respectively 87.3 and 73.2%, and the cancer-specific survival were 96.2 and 92.0%, respectively.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Kidney Neoplasms / surgery. Laparoscopy. Nephrectomy / methods
  • [MeSH-minor] Adult. Aged. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Retroperitoneal Space / surgery. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Oct 1;92(7):1843-55 [11745257.001]
  • [Cites] Urology. 2004 Jun;63(6):1050-4 [15183948.001]
  • [Cites] Eur Urol. 2006 Feb;49(2):314-22; discussion 322-3 [16377073.001]
  • [Cites] J Urol. 2000 Oct;164(4):1153-9 [10992356.001]
  • [Cites] J Urol. 2000 Apr;163(4):1090-5; quiz 1295 [10737472.001]
  • [Cites] J Urol. 1999 Oct;162(4):1277-81 [10492179.001]
  • [Cites] J Urol. 2002 Mar;167(3):1257-62 [11832709.001]
  • [Cites] Eur Urol. 2004 Jun;45(6):692-705 [15149740.001]
  • [Cites] Eur Urol. 2002 Nov;42(5):441-6 [12429151.001]
  • [Cites] Surgery. 1992 May;111(5):518-26 [1598671.001]
  • [Cites] Eur Urol. 2000 Nov;38(5):606-12 [11096244.001]
  • [Cites] J Urol. 1999 Jun;161(6):1776-80 [10332433.001]
  • [Cites] J Urol. 1991 Aug;146(2):278-82 [1830346.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1222-5 [16145374.001]
  • [Cites] Urology. 2003 Dec;62(6):1018-23 [14665347.001]
  • [Cites] J Endourol. 2001 May;15(4):355-9; discussion 375-6 [11394446.001]
  • [Cites] J Urol. 1969 Mar;101(3):297-301 [5765875.001]
  • [Cites] Urology. 2004 Nov;64(5):919-24 [15533478.001]
  • [Cites] J Urol. 2001 Dec;166(6):2095-9; discussion 2099-100 [11696714.001]
  • [Cites] J Endourol. 2005 Sep;19(7):803-7 [16190832.001]
  • [Cites] J Urol. 2005 Jan;173(1):38-41 [15592021.001]
  • [Cites] J Urol. 1993 Jan;149(1):103-5 [8267683.001]
  • (PMID = 18629504.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Zhou J, Zhang ZX, Li DC: Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway. Curr Ther Res Clin Exp; 2010 Aug;71(4):239-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway.
  • Although the CCK-1 receptor has been shown to be highly expressed in resected human pancreatic cancer samples, its role is less clear.
  • OBJECTIVE: The aim of this in vitro study was to investigate the CCK-1 receptor expression and the function of the CCK-CCK-1 receptor pathway in the human pancreatic adenocarcinoma cell line, Mia PaCa-2.
  • 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry were used to detect the cell growth, cell cycle, and apoptosis.
  • Cell invasion ability was observed by invasion assay.
  • Compared with the control group (70.2% [1.5%]), CCK-8S was associated with significant mean (SD) cell proliferation (85.1% [1.7%]; P = 0.039), and the ratio in the S stage of the cell cycle increased significantly (50.5% [1.7%] vs 42.2% [1.4%]; P = 0.021).
  • CCK-8S was also associated with increased Mia PaCa-2 cell invasion ability (123.8 [1.7] vs 102.1 [5.8]; P = 0.005 vs control).
  • Compared with the control group, lorglumide was associated with significantly inhibited cell growth (52.1% [1.8%]; P = 0.002) and cell invasion (77.6% [1.2%]; P = 0.003).
  • Lorglumide also induced G0/G1 cell cycle arrest and apoptosis (27.1% [3-5%] vs 3-7% [0.6%]; P = 0.003 vs control).
  • CONCLUSION: The findings of this in vitro study suggest that CCK may exert a trophic action on the Mia PaCa-2 cell line, while lorglumide inhibited the cell growth and invasion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24688146.001).
  • [ISSN] 0011-393X
  • [Journal-full-title] Current therapeutic research, clinical and experimental
  • [ISO-abbreviation] Curr Ther Res Clin Exp
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3969616
  • [Keywords] NOTNLM ; CCK-1 receptor / MMP-2 / apoptosis / cholecystokinin / pancreatic cancer
  •  go-up   go-down


18. Pouessel D, Culine S: Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Expert Rev Anticancer Ther; 2006 Dec;6(12):1761-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
  • The year 2006 will mark a turning point in the daily management of patients with metastatic renal cell carcinoma.
  • The growing understanding of molecular mechanisms involved in the pathogenesis of the disease, especially clear-cell carcinoma, has led to the development of multiple targeted therapies with significant clinical benefits.
  • Further studies are needed to determine the optimal combinations of these agents in metastatic disease and to assess their impact in the adjuvant setting.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181490.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Immunologic Factors; 0 / Indoles; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Neoplasm Proteins; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 42
  •  go-up   go-down


19. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • L1 cell adhesion molecule (CD171) represents a strongly unfavorable prognostic biomarker for ovarian and endometrial carcinomas.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system.
  • L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


20. Kinoshita T, Inoue H, Kinouchi T, Kobayashi M, Takada T, Hara T, Hatano K, Nonomura N: Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report. Int J Urol; 2010 Mar;17(3):286-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
  • We present the case of a patient with renal cell carcinoma treated preoperatively with sorafenib.
  • Complete resection of the left renal mass measuring 7.2 x 6.6 cm seemed to be difficult at diagnosis because of large renal hilar lymph nodes.
  • Pathological findings revealed that over 90% of the renal tumor was substituted by necrotic fibrotic tissue and that the residual neoplastic component was diagnosed as clear cell carcinoma.
  • At 6 months after radical nephrectomy, a new computed tomography scan revealed no evidence of disease with the disappearance of lung nodules.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzenesulfonates / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Pyridines / administration & dosage

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20409221.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


21. Dyson T, Draganov PV: Squamous cell cancer of the rectum. World J Gastroenterol; 2009 Sep 21;15(35):4380-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell cancer of the rectum.
  • Squamous cell carcinoma of the rectum is a rare malignancy.
  • The clear association seen between Human Papilloma Virus and various squamous cancers has not been firmly established for the squamous cell cancer of the rectum.
  • The presentation is nonspecific and patients tend to present with advanced stage disease.
  • Diagnosis relies on endoscopic examination with biopsy of the lesion.
  • Distinction from squamous cell cancer of the anus can be difficult, but can be facilitated by immunohistochemical staining for cytokeratins.
  • Squamous cell carcinoma of the rectum is a distinct entity and it is of crucial importance for the practicing Gastroenterologist to be thoroughly familiar with this disease.
  • Compared to adenocarcinoma of the rectum and squamous cell cancer of the anal canal, squamous cell carcinoma of the rectum has different epidemiology, etiology, pathogenesis, and prognosis but, most importantly, requires a different therapeutic approach.
  • This review will examine and summarize the available information regarding this disease from the perspective of the practicing gastroenterologist.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Rectal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E45-6 [18300203.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2340-3 [18707873.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):191-7 [18462236.001]
  • [Cites] Br J Surg. 1968 Apr;55(4):273-6 [5644391.001]
  • [Cites] JAMA. 1970 Jun 1;212(9):1511-3 [5467545.001]
  • [Cites] Cancer. 1971 Nov;28(5):1111-7 [5125659.001]
  • [Cites] Am J Surg Pathol. 1978 Mar;2(1):47-54 [637188.001]
  • [Cites] J Pathol. 1979 Nov;129(3):139-47 [529012.001]
  • [Cites] Cancer. 1981 Feb 1;47(3):602-9 [7226009.001]
  • [Cites] Dis Colon Rectum. 1981 May-Jun;24(4):301-4 [7238241.001]
  • [Cites] Dis Colon Rectum. 1983 Mar;26(3):188-91 [6825528.001]
  • [Cites] Dis Colon Rectum. 1983 Apr;26(4):279-82 [6839899.001]
  • [Cites] Vopr Onkol. 1984;30(8):76-83 [6485288.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):338-45 [10733115.001]
  • [Cites] Gastrointest Endosc. 2000 Nov;52(5):683-5 [11060201.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):988-94 [11231953.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):341-6 [11289278.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 May;19(5):719-20 [11343961.001]
  • [Cites] Pathology. 2001 Aug;33(3):312-4 [11523931.001]
  • [Cites] Int J Dermatol. 2001 Jun;40(6):373-9 [11589741.001]
  • [Cites] Dis Colon Rectum. 2002 Jun;45(6):733-42; discussion 742-3 [12072622.001]
  • [Cites] Eur J Surg Oncol. 2002 Sep;28(6):657-60 [12359204.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Aug;16(4):897-906 [12418054.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1535-40 [12432303.001]
  • [Cites] Clin Colorectal Cancer. 2001 May;1(1):55-8 [12445380.001]
  • [Cites] Clin Colorectal Cancer. 2002 Feb;1(4):243-8 [12450423.001]
  • [Cites] J Urol. 2003 Jan;169(1):280 [12478160.001]
  • [Cites] Clin Colorectal Cancer. 2004 Jul;4(2):124-32 [15285819.001]
  • [Cites] Arch Pathol. 1967 Jul;84(1):77-80 [6027742.001]
  • [Cites] Dis Colon Rectum. 1967 Jul-Aug;10(4):288-97 [6037409.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):763-6 [6499614.001]
  • [Cites] Dis Colon Rectum. 1985 Dec;28(12):967-72 [4064861.001]
  • [Cites] J Surg Oncol. 1987 Jun;35(2):117-9 [3586681.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Eur J Surg Oncol. 1987 Oct;13(5):455-8 [3666162.001]
  • [Cites] Dis Colon Rectum. 1988 Mar;31(3):228-35 [3280272.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):323-6 [3282843.001]
  • [Cites] APMIS. 1988 Sep;96(9):839-44 [3166810.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Dis Colon Rectum. 1989 Jul;32(7):593-9 [2737060.001]
  • [Cites] Scand J Gastroenterol. 1989 Dec;24(10):1243-7 [2513640.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1221-3 [2254116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):144-7 [1402312.001]
  • [Cites] Dis Colon Rectum. 1993 Feb;36(2):127-34 [8425415.001]
  • [Cites] Gastrointest Endosc. 1994 Jul-Aug;40(4):442-6 [7926534.001]
  • [Cites] South Med J. 1996 Sep;89(9):921-4 [8790320.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1265-8 [8918436.001]
  • [Cites] Rev Invest Clin. 1996 Nov-Dec;48(6):453-6 [9028152.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 1999 Jan;42(1):102-9 [10211528.001]
  • [Cites] Gastroenterology. 1958 May;34(5):809-39 [13538148.001]
  • [Cites] Gastroenterology. 1960 Oct;39:385-93 [13686938.001]
  • [Cites] Am J Gastroenterol. 1962 Jan;37:48-54 [14006818.001]
  • [Cites] Dis Colon Rectum. 1963 Sep-Oct;6:370-3 [14063163.001]
  • [Cites] Mayo Clin Proc. 1964 Apr;39:249-51 [14141997.001]
  • [Cites] J Pathol Bacteriol. 1955 Jul;70(1):205-12 [13272134.001]
  • [Cites] Br J Surg. 1965 Sep;52:666-8 [14338313.001]
  • [Cites] Eur J Cancer Care (Engl). 2005 Mar;14(1):70-4 [15698388.001]
  • [Cites] Pathology. 2006 Feb;38(1):74-6 [16484015.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):445-7 [16932927.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1393-400 [17661147.001]
  • [Cites] Eur J Surg Oncol. 2008 Jan;34(1):42-8 [17905562.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • (PMID = 19764088.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic
  • [Number-of-references] 76
  • [Other-IDs] NLM/ PMC2747057
  •  go-up   go-down


22. Castellvi J, Garcia A, de la Torre J, Hernandez J, Gil A, Xercavins J, Ramón y Cajal S: Ephrin B expression in epithelial ovarian neoplasms correlates with tumor differentiation and angiogenesis. Hum Pathol; 2006 Jul;37(7):883-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential gene expression studies are identifying new sets of genes with a role in the classification, differential diagnosis, and prognosis of some human tumors.
  • Ephrin B1, a factor involved in angiogenesis, has been shown to be up-regulated in ovarian carcinomas, making it a potential target for cancer treatment.
  • Specimens from 112 benign, borderline, and malignant epithelial ovarian tumors were examined.
  • Ephrin B was detected in 50% of ovarian tumors: clear cell carcinomas (93%), serous carcinomas (74%), mucinous carcinomas (29%), and endometrioid carcinomas (27%).
  • High-grade carcinomas showed greatest ephrin B expression, whereas benign tumors and low-grade carcinomas were rarely positive.
  • A correlation was found between ephrin B expression and microvessel density, supporting the angiogenic role of this factor in ovarian carcinomas.
  • Ephrin B expression was associated with higher rates of disease recurrence and a decrease in overall survival.
  • A distinctive pattern of ephrin B expression was observed in ovarian tumors: high-grade tumors and clear cell and serous carcinomas show higher expression, correlating with the aggressiveness.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Differentiation. Female. Humans. Immunohistochemistry. Microcirculation. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784989.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ephrin-B1
  •  go-up   go-down


23. Lim MC, Lee HS, Kang S, Seo SS, Lee BY, Park SY: Minimizing tumor burden by extensive cytoreductive surgery decreases postoperative venous thromboembolism in ovarian clear cell carcinoma. Arch Gynecol Obstet; 2010 Feb;281(2):329-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimizing tumor burden by extensive cytoreductive surgery decreases postoperative venous thromboembolism in ovarian clear cell carcinoma.
  • PURPOSE: A venous thromboembolism (VTE) is prevalent in patients with ovarian clear cell carcinoma (OCCC).
  • A VTE was associated with disease status only (P=0.042).
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Ovarian Neoplasms / complications. Venous Thromboembolism / complications

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458955.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


24. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F: Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer; 2008 Jan 1;122(1):91-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
  • Epithelial ovarian carcinoma (EOC) spreads by implantation of tumor cells onto the human peritoneal mesothelial cells (HPMCs) lining the peritoneal cavity.
  • The aim of this study was to determine whether the stromal cell-derived factor-1alpha (SDF-1alpha)/CXCR4 axis is involved in the interaction of EOC cells with HPMCs in peritoneal metastasis.
  • We next examined whether SDF-1alpha played roles in EOC progression, including in proliferation, cell motility, attachment to HPMCs, and the in vivo development of peritoneal metastasis through CXCR4.
  • Of the 36 carcinomas, 16 cases (44.4%) were positive for CXCR4 immunoexpression.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Animals. Anti-HIV Agents / pharmacology. Blotting, Western. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / secondary. Cell Adhesion / physiology. Cell Movement / physiology. Coculture Techniques. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Heterocyclic Compounds / pharmacology. Humans. Immunoenzyme Techniques. Mice. Middle Aged. Mitogen-Activated Protein Kinases / metabolism. Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Peritoneum / metabolism. Peritoneum / pathology. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17893878.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR4; 155148-31-5 / JM 3100; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


25. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer; 2005 Apr 15;103(8):1631-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
  • BACKGROUND: It was demonstrated previously that the Snail family of transcription factors and Smad-interacting protein 1 (Sip1) regulate E-cadherin and matrix metalloproteinase 2 (MMP-2) expression, cellular morphology, and invasion in carcinoma.
  • For the current study, the authors analyzed the relation between the expression of Snail, Slug, and Sip1; the expression of MMP-2 and E-cadherin; and clinical parameters in patients with metastatic ovarian and breast carcinoma.
  • METHODS: One hundred one fresh-frozen, malignant effusions from patients who were diagnosed with gynecologic carcinomas (78 ovarian carcinomas and 23 breast carcinomas) were studied for mRNA expression of Snail, Slug, Sip1, MMP-2, and E-cadherin using reverse transcriptase-polymerase chain reaction analysis.
  • Snail mRNA and E-cadherin protein expression levels also were studied in ovarian carcinoma effusions using in situ hybridization and immunocytochemistry.
  • RESULTS: E-cadherin mRNA expression was lower in breast carcinoma (P = 0.001), whereas Snail expression was higher (P = 0.003).
  • The Snail/E-cadherin ratio (P < 0.001) and the Sip1/E-cadherin ratio (P = 0.002) were higher in breast carcinomas.
  • Sip1 mRNA expression (P < 0.001) and Slug mRNA expression (P < 0.001) were correlated with the expression of MMP-2 in ovarian carcinomas.
  • The Sip1/E-cadherin ratio was higher in primary ovarian carcinomas at the time of diagnosis compared with postchemotherapy ovarian carcinoma effusions (P = 0.003), higher in Stage IV tumors compared with Stage III tumors (P = 0.049), and higher in pleural effusions compared with peritoneal effusions (P = 0.044).
  • In a univariate survival analysis of patients with ovarian carcinoma, a high Sip1/E-cadherin ratio predicted poor overall survival (P = 0.018).
  • High E-cadherin mRNA expression predicted better disease-free survival (P = 0.023), with a similar trend for a low Slug/E-cadherin ratio (P = 0.07).
  • High Snail mRNA expression predicted shorter effusion-free survival (P = 0.008), disease-free survival (P = 0.03), and overall survival (P = 0.008) in patients with breast carcinoma.
  • CONCLUSIONS: Transcription factors that regulate E-cadherin were expressed differentially in metastatic ovarian and breast carcinoma.
  • Snail may predict a poor outcome in patients who have breast carcinoma metastatic to effusions.
  • E-cadherin expression generally was conserved in effusions from patients with ovarian carcinoma, but the subset of patients with postulated Sip1-induced repression of this adhesion molecule had a significantly worse outcome.
  • This finding was in agreement with the stronger suppression of E-cadherin by Snail and Sip1 in breast carcinoma effusions, a clinical condition associated with extremely poor survival.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Cadherins / genetics. Cadherins / metabolism. Carcinoma, Ductal / genetics. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / secondary. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15742334.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Drosophila Proteins; 0 / Homeodomain Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / ZEB2 protein, human; 0 / snail family transcription factors; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


26. Rotellini M, Fondi C, Paglierani M, Stomaci N, Raspollini MR: Clear cell carcinoma of the bladder in a patient with a earlier clear cell renal cell carcinoma: a case report with morphologic, immunohistochemical, and cytogenetical analysis. Appl Immunohistochem Mol Morphol; 2010 Jul;18(4):396-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the bladder in a patient with a earlier clear cell renal cell carcinoma: a case report with morphologic, immunohistochemical, and cytogenetical analysis.
  • Clear cell transitional carcinoma of the bladder is a subtype of transitional carcinoma that morphologically resembles a clear cell renal cell carcinoma.
  • Although kidney tumors do not frequently metastasize to the bladder, the recurrence after a clear cell renal cell carcinoma has been reported even several years after nephrectomy.
  • We report the case of a male patient to whom radical nephrectomy for a clear cell renal cell carcinoma has been done, with a bladder tumor featuring polygonal cells with abundant clear cytoplasm deeply infiltrating the vesical wall.
  • We discuss the morphologic features, the immunohistochemical staining with a new marker and the UroVysion FISH analysis to achieve a definitive diagnosis.

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216403.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Hill R, Song Y, Cardiff RD, Van Dyke T: Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell; 2005 Dec 16;123(6):1001-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our understanding of cancer has largely come from the analysis of aberrations within the tumor cell population.
  • Yet it is increasingly clear that the tumor microenvironment can significantly influence tumorigenesis.
  • Recent analyses of some human carcinomas have shown tumor-suppressor gene mutations within the stroma, suggesting that the interplay among multiple cell types can select for aberrations nonautonomously during tumor progression.
  • We demonstrate that this indeed occurs in a mouse model of prostate cancer where epithelial cell cycle disruption via cell-specific inhibition of pRb function induces a paracrine p53 response that suppresses fibroblast proliferation in associated stroma.
  • [MeSH-minor] Actins / analysis. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Antigens, Polyomavirus Transforming / genetics. Cell Proliferation. Connective Tissue / pathology. Disease Models, Animal. Gene Deletion. Genotype. Keratin-8. Keratins / analysis. Loss of Heterozygosity / genetics. Male. Mice. Mice, Knockout. Mice, Transgenic. Models, Biological. Paracrine Communication. Prostate / metabolism. Prostate / pathology. Prostatic Neoplasms / genetics. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Retinoblastoma Protein / metabolism. S100 Proteins / analysis


28. Suzuki N, Tamada Y, Shigirahara K, Suzuki A, Susumu N, Ishida I, Aoki D: Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):996-1006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen.
  • A human ovarian clear cell adenocarcinoma cell line (RMG-I) was used to immunize KM mice, and hybridoma supernatant was obtained by a standard method employing enzyme-linked immunosorbent assay screening.
  • Immunohistochemical reactivity of this antibody (human monoclonal antibody for ovarian clear cell carcinoma-2 [HMOCC-2]) with ovarian cancer was assessed, while its specificity was analyzed by Western blotting.
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028379.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CA-125 Antigen
  •  go-up   go-down


29. Németh I, Sükösd F, Béli L, Kiss A, Pajor L, Mikó T, Iványi B: [Adult renal neoplasms in the material of the Pathology Department of the Szeged University]. Orv Hetil; 2005 Apr 3;146(14):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 86.7% of all the tumours (n = 407) were malignant.
  • Among the malignant tumours, the frequency of renal cell carcinomas was 91.1% (n = 371).
  • 88.4% of the renal cell carcinomas (n = 328) were of conventional type, 5.6% (n = 21) were papillary and 4% (n = 15) were chromophobe.
  • The authors observed 3 Bellini duct, 1 mucinous tubular and 3 non-classifiable carcinomas, with a combined incidence of 1.8%.
  • 84.5% of the conventional carcinomas were clear cell (n = 277), 8.8% were eosinophilic granular (n = 29), 3.9% were multilocular cystic (n = 13) and 2.7% were sarcomatoid carcinomas (n = 9).
  • The median age of the patients with conventional carcinoma was 60 (median, range: 25-84), in the papillary group it was 62 (43-78), and in the chromophobe group was 59 (17-77).
  • The median age of patients affected by transitional cell carcinoma was 64 (range: 45-81).
  • In 13 oncocytoma cases, the tumours were initially diagnosed as malignant.
  • CONCLUSIONS: Adult malignant renal tumours affect mainly patients around the age of 60.
  • The commonest diagnosis was clear cell carcinoma of conventional type.
  • The incidence of clear cell carcinoma was 5% higher than that reported in the literature (84.5% vs 70-80%) whereas that of papillary carcinoma was 5% lower (5% vs 10-15%).
  • In comparison with the literature data, oncocytomas were relatively common (8% instead of 3%), and not rarely, it was difficult to distinguish them from renal cell carcinomas.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / pathology. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / epidemiology. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / epidemiology. Adenoma, Oxyphilic / pathology. Adult. Aged. Angiomyolipoma / epidemiology. Angiomyolipoma / pathology. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / epidemiology. Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / pathology. Female. Humans. Hungary / epidemiology. Male. Middle Aged. Nephrectomy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889540.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


30. Yetkin G, Uludağ M, Ozağari A: Solitary colonic metastasis of renal cell carcinoma. Acta Chir Belg; 2008 Mar-Apr;108(2):264-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary colonic metastasis of renal cell carcinoma.
  • We report a rare case of a solitary metastasis of a renal cell carcinoma which manifested as a primary colonic tumour.
  • A 60-year-old male patient who had undergone a right radical nephrectomy 5 years previously for renal cell carcinoma, presented with a history of dyspepsia and pain in the right upper abdomen.
  • Postoperative histological examination revealed that the tumour was a metastatic renal cell carcinoma of the clear cell type.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Colonic Neoplasms / secondary. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18557158.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


31. Vu CK, Chang F, Doig L, Meenan J: Metastatic lymph node impostor in pancreatic cystadenocarcinoma. JOP; 2005 Mar;6(2):189-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We report an interesting case of a man with chronic lymphocytic leukemia, who presented with the diagnostic problem of a pancreatic solid-cystic lesion and multiple malignant-looking peri-pancreatic lymphadenopathy on EUS.
  • The absence of adenocarcinoma involvement of the lymph nodes prompted surgery on the pancreatic lesion with a curative intent.
  • Pancreatic mucinous cystadenocarcinoma was diagnosed and a sub-total pancreatectomy was performed with clear resection margins.
  • Systemic lymphoproliferative disease, as in this case, can masquerade as metastatic adenocarcinoma lymph nodes on EUS.
  • EUS-FNA is useful in diagnosing lymphoproliferative disease.
  • [MeSH-major] Cystadenocarcinoma / diagnosis. Cystadenocarcinoma / secondary. Lymphatic Metastasis / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Endosonography. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / ultrasonography. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymph Nodes / ultrasonography. Male. Pancreas / pathology. Pancreas / surgery. Pancreas / ultrasonography. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767737.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


32. Picken MM: The evolving concept of renal neoplasia: impact of emerging molecular and electron microscopic studies. Ultrastruct Pathol; 2005 May-Aug;29(3-4):277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classification of renal tumors has evolved from one that initially encompassed only 2 types of tumors, i.e., clear and granular cell carcinomas, to the markedly expanded recent classification that incorporates new entities, some of which are primarily defined by specific molecular abnormalities.
  • Despite these advances, a single tumor category, clear cell carcinoma, still incorporates the majority (approximately 70%) of renal tumors.
  • Electron microscopic studies have been pivotal in defining the spectrum of oncocytoma-chromophobe renal cell carcinoma.
  • Cytoplasmic eosinophilia found in some renal cell carcinomas currently classified as clear cell type is under intense study.
  • Tumors that have recently emerged from this group include tumors with translocations involving chromosome Xp11.2, carcinomas associated with neuroblastoma and epithelioid angiomyolipoma.
  • The author concludes that although the routine application of electron microscopy to kidney tumor diagnosis may not be practical, systematic ultrastructural studies of these tumors may aid in the definition of new entities.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036881.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


33. Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, Moerman P, Vergote I, Amant F: Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer; 2009 Jul 21;101(2):244-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological subtypes were as follows: serous (90%), clear cell (3%) and endometrioid (6%) carcinoma.
  • Response according to RECIST was as follows: 2 (7%) complete remission, 20 (67%) partial remission, 6 (20%) stable disease and 2 (7%) progressive disease (PD).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Prospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):211-7 [17239941.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):710-8 [17182981.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):160-3 [17490737.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):190-3 [17825394.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):92-9 [11277657.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):454-8 [12366662.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):74-7 [12488296.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):653-8 [15196860.001]
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):327-31 [2351315.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):123-7 [8690284.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):140-4 [10094895.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):461-3 [10366480.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:273-7 [16515603.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):986-90 [16803473.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):926-34 [17397905.001]
  • (PMID = 19568245.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2720217
  •  go-up   go-down


36. Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE: BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet; 2009 Aug;76(2):161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA2 alteration is important in clear cell carcinoma of the ovary.
  • BRCA2 has been shown to play a significant role in hereditary ovarian carcinoma.
  • Several cases of clear cell carcinoma (CCC) of the ovary containing BRCA2 mutations have been identified.
  • The 5-year disease-specific survival probability for patients with a BRCA2 alteration is 87.5%, compared to only 40% for those patients without a BRCA2 alteration (p = 0.39).
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. BRCA2 Protein / genetics. Mutation / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656163.001).
  • [ISSN] 1399-0004
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BRCA2 Protein
  •  go-up   go-down


37. Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, Vieira RH, Lopes CS: Biological relevance of E-cadherin-catenin complex proteins in primary epithelial ovarian tumours. Gynecol Obstet Invest; 2005;60(2):75-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry was used to evaluate the expression of these proteins in 154 epithelial ovarian tumours, consisting of 17 benign, 33 borderline and 104 malignant tumours.
  • In borderline tumours, the immunoexpression pattern of E-cadherin (p = 0.014) and alpha-catenin (p = 0.030) associated with histological type.
  • In malignant tumours, the immunoexpression pattern of E-cadherin was related with histological type (p = 0.001).
  • The immunoexpression pattern of beta-catenin associated with histological type and tumour differentiation (p = 0.005, p = 0.025, respectively).
  • The preserved phenotype of beta-catenin associated with endometrioid carcinomas, while reduced beta-catenin associated with poorly differentiated serous and clear cell carcinomas.
  • Although the reduced phenotype was the most frequent immunoexpression observed for all proteins of the E-cadherin-catenin complex in epithelial ovarian tumours, only beta-catenin showed a significant difference between benign, borderline and malignant tumours (p = 0.045), since borderline and malignant tumours most frequently showed the reduced phenotype.
  • The immunohistochemical profile of beta-catenin was shown to be of biological relevance: reduced beta-catenin was correlated with loss of tumour differentiation and serous carcinomas that are known to depict aggressive biological behaviour in epithelial ovarian tumours.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Desmoplakins. Female. Humans. Immunohistochemistry. Middle Aged. alpha Catenin. beta Catenin. gamma Catenin

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15785075.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Desmoplakins; 0 / JUP protein, human; 0 / Trans-Activators; 0 / alpha Catenin; 0 / beta Catenin; 0 / gamma Catenin
  •  go-up   go-down


38. Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS: p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res; 2008 Aug 15;68(16):6524-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This tumorigenic activity is associated with the ability of p70(S6K) to repress E-cadherin through the up-regulation of Snail. p70(S6K) activation induced phenotypic changes consistent with EMT in ovarian cancer cells: The cells lost epithelial cell morphology, acquired fibroblast-like properties, and showed reduced intercellular adhesion.
  • Targeting p70(S6K) may thus be a useful strategy to impede cancer cell invasion and metastasis.
  • [MeSH-major] Cell Differentiation. Epithelial Cells / pathology. Mesoderm / pathology. Ovarian Neoplasms / pathology. Ribosomal Protein S6 Kinases, 70-kDa / physiology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Blotting, Western. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / secondary. Cell Communication. Cell Nucleus / metabolism. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Female. Humans. Immunoenzyme Techniques. Immunoprecipitation. Microscopy, Fluorescence. Middle Aged. Neoplasm Invasiveness. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Transcription, Genetic. Tumor Cells, Cultured. Zinc Fingers


39. Yang YH, Chen RJ, Lin MC, Cheng SP, Chang TC: Synchronous primary ovarian and endometrial cancer with a fair prognosis in a young woman. Taiwan J Obstet Gynecol; 2010 Mar;49(1):97-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology


40. Kwon YS, Nam JH, Choi G: Clear cell adenocarcinoma arising in endometriosis of a previous episiotomy site. Obstet Gynecol; 2008 Aug;112(2 Pt 2):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma arising in endometriosis of a previous episiotomy site.
  • BACKGROUND: Malignant transformation of endometriosis in an episiotomy site is rare.
  • Biopsy revealed a clear cell adenocarcinoma arising in endometriosis.
  • CONCLUSION: Patients who experience a recurrence of extragonadal endometriosis after prior therapy should be monitored carefully for malignant degeneration.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Endometriosis / complications. Episiotomy / adverse effects. Iatrogenic Disease. Vulvar Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669770.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Seijas BP, Franco FL, Sastre RM, García AA, López-Cedrún Cembranos JL: Metastatic renal cell carcinoma presenting as a parotid tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 May;99(5):554-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic renal cell carcinoma presenting as a parotid tumor.
  • Metastases of malignancies to the parotid region are relatively infrequent (21%-42% of all malignant tumors 1 ), but metastases of infraclavicular origin are infrequent (0.16%-4% 1,2 ).
  • From 1986 to 1998, only 17 cases of parotid metastases of renal clear cell carcinoma were documented in the literature reviewed.
  • In this paper we report a case of a patient with a parotid tumor which was the first manifestation of distant disease.
  • It was only once the tumor was surgically removed that the histopathology allowed the diagnosis of the primary tumor; namely a renal clear cell adenocarcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Parotid Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Aged. Diagnosis, Differential. Fatal Outcome. Humans. Immunohistochemistry. Male. Neprilysin / analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829877.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


42. Verine J, Lehmann-Che J, Soliman H, Feugeas JP, Vidal JS, Mongiat-Artus P, Belhadj S, Philippe J, Lesage M, Wittmer E, Chanel S, Couvelard A, Ferlicot S, Rioux-Leclercq N, Vignaud JM, Janin A, Germain S: Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One; 2010;5(4):e10421
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.
  • BACKGROUND: We have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available.
  • In contrast, angptl4 mRNA was neither expressed in 94% non-ccRCC renal tumors (papillary RCCs (n = 46), chromophobe RCCs (n = 28), and oncocytomas (n = 9)), nor in non-renal clear cell carcinomas (n = 39).
  • Angptl4 expression was also examined in tumors associated (n = 23) or not associated (n = 66) with VHL disease.
  • CONCLUSIONS/SIGNIFICANCE: Angptl4 mRNA expression was highly associated with ccRCC (p = 1.5 10(-49), Chi square test) allowing to define its expression as a diagnosis marker for primary ccRCC.
  • Moreover, angptl4 mRNA allows to discriminate the renal origin of metastases of clear-cell carcinomas arising from various organs.
  • [MeSH-major] Angiopoietins / genetics. Carcinoma, Renal Cell / diagnosis. Molecular Diagnostic Techniques. RNA, Messenger / analysis
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Humans. In Situ Hybridization. Neoplasm Metastasis. RNA, Neoplasm / analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9 [11493696.001]
  • [Cites] Hum Pathol. 2009 Dec;40(12):1671-8 [19695674.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1521-8 [12707035.001]
  • [Cites] Histopathology. 2004 Nov;45(5):452-9 [15500648.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] PLoS Med. 2006 Jan;3(1):e13 [16318415.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):51-68 [16512599.001]
  • [Cites] Actas Urol Esp. 2006 Mar;30(3):281-6 [16749584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6 [17130448.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):554-8 [17540307.001]
  • [Cites] Annu Rev Pathol. 2007;2:145-73 [18039096.001]
  • [Cites] Histopathology. 2008 Jan;52(2):158-66 [18036175.001]
  • [Cites] Cell. 2008 Apr 4;133(1):66-77 [18394990.001]
  • [Cites] Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8 [18481984.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1051-9 [18496143.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4726-34 [18676741.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1462-7 [18685487.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] J Urol. 2009 Feb;181(2):849-60 [19095258.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):241-7 [18941400.001]
  • [Cites] FASEB J. 2009 Mar;23(3):940-9 [19019854.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1119-32 [19269025.001]
  • [Cites] BMC Med. 2009;7:9 [19291283.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):739-48 [19238077.001]
  • [Cites] J Biol Chem. 2009 May 1;284(18):11942-52 [19246456.001]
  • [Cites] Int J Urol. 2009 May;16(5):432-43 [19453547.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):474-82 [19391132.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):764-71 [19576851.001]
  • [Cites] J Pathol. 2002 Feb;196(2):186-93 [11793370.001]
  • (PMID = 20454689.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANGPTL4 protein, human; 0 / Angiopoietins; 0 / Biomarkers; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2861680
  •  go-up   go-down


43. Graham AD, Williams AR, Salter DM: TTF-1 expression in primary ovarian epithelial neoplasia. Histopathology; 2006 May;48(6):764-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681695.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


44. Wang Y, Wu R, Cho KR, Shedden KA, Barder TJ, Lubman DM: Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques. Mol Cell Proteomics; 2006 Jan;5(1):43-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques.
  • A two-dimensional liquid mapping method was used to map the protein expression of eight ovarian serous carcinoma cell lines and three immortalized ovarian surface epithelial cell lines.
  • The resulting corrected maps can then be compared using hierarchical clustering to produce dendrograms indicating the relationship between different cell lines.
  • It was found that several of the ovarian surface epithelial cell lines clustered together, whereas specific groups of serous carcinoma cell lines clustered with each other.
  • Although there is limited information on the current biology of these cell lines, it was shown that the protein expression of certain cell lines is closely related to each other.
  • Other cell lines, including one ovarian clear cell carcinoma cell line, two endometrioid carcinoma cell lines, and three breast epithelial cell lines, were also mapped for comparison to show that their protein profiles cluster differently than the serous samples and to study how they cluster relative to each other.
  • In addition, comparisons can be made between proteins differentially expressed between cell lines that may serve as markers of ovarian serous carcinomas.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16141455.001).
  • [ISSN] 1535-9476
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100104; United States / NCI NIH HHS / CA / R01CA90503; United States / NIGMS NIH HHS / GM / R01GM49500; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01CA10010
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Proteome
  •  go-up   go-down


45. Bukowski RM: Renal cell carcinoma: a new era? Clin Genitourin Cancer; 2005 Dec;4(3):155
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma: a new era?
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / genetics

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Genitourin Cancer. 2005 Dec;4(3):175-80 [16425985.001]
  • [CommentOn] Clin Genitourin Cancer. 2005 Dec;4(3):181-6 [16425986.001]
  • [CommentOn] Clin Genitourin Cancer. 2005 Dec;4(3):167-74 [16425993.001]
  • (PMID = 16425982.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


46. Boruban MC, Jaishuen A, Sirisabya N, Li Y, Zheng HG, Deavers MT, Kavanagh JJ: Ovarian endometriosis associated with carcinoma and sarcoma: case report. Eur J Gynaecol Oncol; 2008;29(4):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian endometriosis associated with carcinoma and sarcoma: case report.
  • Endometriosis is a common clinical disorder that shares certain characteristics, metastasis and recurrence, with malignant neoplasms.
  • Most malignant ovarian tumors arising from endometriosis are clear cell carcinoma or endometrioid adenocarcinoma.
  • The pathologic findings revealed bilateral endometrioid adenofibroma of low malignant potential, which was associated with endometrioid intraepithelial carcinoma in the left ovary and high-grade sarcoma in the right ovary.
  • The optimal treatment for endometriosis-associated ovarian cancer depends on the type of malignancy; simultaneously occurring multiple tumor types should be treated individually.
  • [MeSH-major] Carcinoma / etiology. Endometriosis / complications. Ovarian Diseases / complications. Ovarian Neoplasms / etiology. Sarcoma / etiology


47. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR: Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol; 2006 Nov;103(2):684-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
  • OBJECTIVE: Uterine mixed malignant mullerian tumors (MMMT) have traditionally been excluded from clinical trials of endometrial cancer because of a belief that they are more correctly included in the sarcoma category.
  • The current study was undertaken to compare outcomes, stage for stage, of uterine MMMT with poor prognosis endometrial adenocarcinomas.
  • Cases were matched by age, stage, performance status, and surgical procedure to controls consisting of grade 3 endometrioid, papillary serous, and clear cell endometrial carcinomas from the same time period.
  • Approximately half of the patients (53%) had stage III or IV disease.
  • Of the controls, 31 (69%) had grade 3 endometrioid, 11 (24%) papillary serous, and 3 (7%) clear cell carcinoma.
  • Patients with early stage disease (stage I or II) had shorter median survival than controls, 26 months (range 3-7) vs. 95 months (range 4-123) (P = 0.003).
  • There was no difference in median survival when comparing advanced disease (stage III or IV) to matched controls, 15 months (range 0.5-70) vs. 19 months (range 0.5-100) (P = NS).
  • CONCLUSIONS: Patients with uterine MMMT have a poorer prognosis than those patients with high grade epithelial tumors, especially for those with early stage disease.
  • Given the discrepancy in survival, these patients should not be included in studies of endometrial carcinoma.
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Case-Control Studies. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies


48. Zhang T, Zhou NK, Zhang JM, Liang CY, Liu X, Tian XD: [Comparison of the biodistribution and PET imaging with (11)C-PDT and (18)F-FDG in the mouse model of lung adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Feb;32(2):103-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the biodistribution and PET imaging with (11)C-PDT and (18)F-FDG in the mouse model of lung adenocarcinoma].
  • OBJECTIVE: The objective of this study was to compare the biodistribution and PET imaging of (11)C-PDT and (18)F-FDG in a mouse model of lung adenocarcinoma, and to evaluate the value of (11)C-PDT as a new tracer for PET imaging of lung cancer.
  • METHODS: Twenty four lung adenocarcinoma-bearing mice were randomly divided into two groups, 12 each.
  • The tumor PET images with (11)C-PDT and (18)F-FDG were all clear.
  • [MeSH-major] Adenocarcinoma / metabolism. Carbon Radioisotopes / pharmacokinetics. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / metabolism. Podophyllotoxin / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Kidney / metabolism. Kidney / radionuclide imaging. Liver / metabolism. Liver / radionuclide imaging. Mice. Myocardium / metabolism. Positron-Emission Tomography. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403239.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


49. Chinen K, Tokuda Y, Fujiwara M, Fujioka Y: Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract; 2010 Oct 15;206(10):682-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature.
  • Although PTTM has drawn increased attention as a fatal complication of gastric carcinoma (GC), comprehensive studies are still lacking.
  • They showed clear morphological evidence of PH.
  • The other 3 patients had PTTM as an incidental finding irrespective of clinical manifestations or PH.
  • All PTTM cases were associated with advanced GC, with a histology of adenocarcinoma of poorly differentiated type (n=4) or signet-ring cell type (n=2).
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Signet Ring Cell / secondary. Lung Neoplasms / secondary. Neoplastic Cells, Circulating / pathology. Stomach Neoplasms / pathology. Thrombotic Microangiopathies / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Autopsy. Cell Differentiation. Female. Humans. Hypertension, Pulmonary / etiology. Hypertension, Pulmonary / pathology. Immunohistochemistry. Male. Middle Aged. Thromboplastin / analysis. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20554399.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9035-58-9 / Thromboplastin
  •  go-up   go-down


50. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchiò C, Geyer FC, Savage K, Parry S, Fenwick K, Tamber N, Mackay A, Dexter T, Jameson C, McCluggage WG, Williams A, Graham A, Faratian D, El-Bahrawy M, Paige AJ, Gabra H, Gore ME, Zvelebil M, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res; 2009 Apr 1;15(7):2269-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
  • PURPOSE: To identify therapeutic targets in ovarian clear cell carcinomas, a chemoresistant and aggressive type of ovarian cancer.
  • EXPERIMENTAL DESIGN: Twelve ovarian clear cell carcinoma cell lines were subjected to tiling path microarray comparative genomic hybridization and genome-wide expression profiling analysis.
  • The prevalence of PPM1D amplification and mRNA expression was determined using chromogenic in situ hybridization and quantitative real-time reverse transcription-PCR in a cohort of pure ovarian clear cell carcinomas and on an independent series of unselected epithelial ovarian cancers.
  • PPM1D had significantly higher levels of mRNA expression in ovarian clear cell carcinoma cell lines harboring gains/amplifications of 17q23.2.
  • PPM1D inhibition revealed that PPM1D expression and phosphatase activity are selectively required for the survival of ovarian clear cell carcinoma cell lines with 17q23.2 amplification.
  • PPM1D amplification was significantly associated with ovarian clear cell carcinoma histology (P = 0.0003) and found in 10% of primary ovarian clear cell carcinomas.
  • PPM1D expression levels were significantly correlated with PPM1D gene amplification in primary ovarian clear cell carcinomas.
  • CONCLUSION: Our data provide strong circumstantial evidence that PPM1D is a potential therapeutic target for a subgroup of ovarian clear cell carcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Cyclopentanes / pharmacology. Gene Amplification. Ovarian Neoplasms / genetics. Phosphoprotein Phosphatases / genetics. Thiophenes / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Chromosome Aberrations. Chromosomes, Human, Pair 17. Comparative Genomic Hybridization. Enzyme Inhibitors / pharmacology. Female. Gene Expression Profiling. Genes, p53. Humans. Mutation. RNA Interference. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19293255.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCT007093; 0 / Cyclopentanes; 0 / Enzyme Inhibitors; 0 / Thiophenes; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.16 / protein phosphatase 2C
  •  go-up   go-down


51. Huang KH, Chung SD, Huang SY, Chueh SC, Chen CA, Chen J: Coexistence of ovarian cancer and renal cell carcinoma. J Formos Med Assoc; 2007 Mar;106(3 Suppl):S15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of ovarian cancer and renal cell carcinoma.
  • Coexistence of ovarian cancer and renal cell carcinoma (RCC) is extremely rare.
  • Pathologic examination revealed right ovarian clear-cell carcinoma with peritoneal, omental, and fallopian tube metastasis, and conventional clear-cell renal carcinoma.
  • Ovarian clear-cell carcinoma showed weakly positive results in EMA staining and negative results in ER, PR, 34betaE12, and vimentin staining.


52. Lu Y, Liu MH, Zheng Y, Guo SW, Liu XS: [Clinicopathological features of 67 cases of endometriosis-associated epithelial ovarian carcinoma.]. Zhonghua Fu Chan Ke Za Zhi; 2009 Nov;44(11):832-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features of 67 cases of endometriosis-associated epithelial ovarian carcinoma.].
  • OBJECTIVE: To investigate clinicopathological features of endometriosis-associated epithelial ovarian carcinoma.
  • METHODS: Retrospective follow-up study, clinicopathological data from patients with ovarian epithelial carcinoma were retrieved, analyzed and compared.
  • RESULT: Seven hundred and twenty-seven epithelial ovarian carcinoma patients were identified and their clinicopathological data retrieved.
  • The frequency of malignant tumors arising from ovarian endometriosis in this case series was estimated to be 0.87% (34/3890).
  • Patients with coexisting ovarian endometriosis were mostly diagnosed at stage I (P = 0.000) and having subtype of clear-cell (P = 0.000), while other patients were mostly diagnosed at stage III (P = 0.001), and having subtype of serous carcinoma (P = 0.000).
  • CONCLUSION: Patients of endometriosis-associated epithelial ovarian carcinoma, especially patients with tumors arising from endometriosis, were found to be younger, having a significant lower stage and a better survival, and were mostly diagnosed with the subtype of clear-cell.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Endometriosis

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079035.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


53. Li GH, Qian W, Song GQ, Hou XH: Effect of vasoactive intestinal peptide on gastric adenocarcinoma. J Gastroenterol Hepatol; 2007 Aug;22(8):1328-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of vasoactive intestinal peptide on gastric adenocarcinoma.
  • However, the effect of VIP on gastric adenocarcinoma is not clear yet.
  • The aim of the present study was to investigate the effect of VIP on gastric adenocarcinoma, especially autocrine regulation of VIP on gastric adenocarcinoma.
  • METHODS: VIP mRNA and protein, and its receptor mRNA (VIPR(1) and VIPR(2)) were measured in 15 normal antrum mucosa, 20 gastric adenocarcinoma tissues, and the SGC7901 gastric adenocarcinoma cell line by using reverse transcription polymerase chain reaction (RT-PCR), immunohistochemistry, or radioimmunoassay methods.
  • The effect of the VIP protein and its antagonist (D-p-Cl-Phe6, Leu17)-VIP on SGC7901 cell growth was detected by methylthiazolyldiphenyl-tetrazolium bromide (MTT) method.
  • RESULTS: The VIP mRNA expression in gastric adenocarcinoma tissues was significantly higher than that in normal antrum mucosa (P < 0.01).
  • The VIP-positive immunoreactivity cells existed in 40% of gastric adenocarcinoma tissues, but not in normal tissues (P < 0.01).
  • The VIP-positive immunoreactivity nerve fibers were observed in normal tissues, but not in adenocarcinoma tissues (P < 0.01).
  • The expression rate of VIPR(1) mRNA in adenocarcinoma tissues was significantly lower than that in normal tissues, but that of VIPR(2) mRNA in the two kinds of tissues were similar (P > 0.05).
  • In addition, the expression quantity of VIPR(1) mRNA and VIPR(2) mRNA in adenocarcinoma tissues was significantly lower than that in normal tissues (P < 0.05).
  • CONCLUSIONS: The expression of VIP mRNA upregulates, but the expressions of VIPR mRNA downregulates in gastric adenocarcinoma tissues.
  • The gastric adenocarcinoma tissues contain endocrine cells to secrete VIP, which show malignant specialities.
  • [MeSH-major] Adenocarcinoma / metabolism. Stomach Neoplasms / metabolism. Vasoactive Intestinal Peptide / physiology
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Humans. Immunohistochemistry. Male. Middle Aged. Ornithine Decarboxylase / metabolism. Proto-Oncogene Proteins c-myb / metabolism. RNA, Messenger / metabolism. Receptors, Vasoactive Intestinal Polypeptide, Type I. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559364.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myb; 0 / RNA, Messenger; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 37221-79-7 / Vasoactive Intestinal Peptide; EC 4.1.1.17 / Ornithine Decarboxylase
  •  go-up   go-down


54. Fitzgerald TJ, Wang T, Goel HL, Huang J, Stein G, Lian J, Davis RJ, Doxsey S, Balaji KC, Aronowitz J, Languino LR: Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Rev Anticancer Ther; 2008 Jun;8(6):967-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention.
  • Adenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men.
  • Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):433-42 [14755675.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Biol. 2004 Aug 2;166(3):407-18 [15289498.001]
  • [Cites] Radiat Res. 1992 Jun;130(3):281-8 [1594753.001]
  • [Cites] Adv Cancer Res. 1996;68:183-223 [8712068.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2203-9 [10232609.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):99-111 [10388524.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1859-66 [15547727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1454-9 [15665096.001]
  • [Cites] J Cell Biol. 2000 May 1;149(3):741-54 [10791986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1676-81 [11172010.001]
  • [Cites] Mol Pathol. 2001 Jun;54(3):133-7 [11376123.001]
  • [Cites] Trends Mol Med. 2001 Dec;7(12):542-7 [11733216.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26321-6 [12015321.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4263-72 [12154028.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44969-79 [12297496.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):6702-9 [12493743.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 7;311(1):174-8 [14575710.001]
  • [Cites] Int J Radiat Biol. 2003 Sep;79(9):709-20 [14703944.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):376-87 [15864279.001]
  • [Cites] Prostate. 2005 Jun 15;64(1):83-91 [15651037.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1378-90 [16247454.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2339-48 [16331261.001]
  • [Cites] Laryngoscope. 2006 Jul;116(7):1228-31 [16826065.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 22;351(3):726-32 [17087916.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):163-80 [17084981.001]
  • [Cites] Nature. 2007 Jan 25;445(7126):442-6 [17251981.001]
  • [Cites] Oncogene. 2007 Feb 1;26(5):652-61 [16909121.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1155-62 [17283150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3189-94 [17360627.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):142-9 [17303404.001]
  • [Cites] J Pathol. 2007 Jul;212(3):316-24 [17503414.001]
  • [Cites] Int J Radiat Biol. 2007 Nov-Dec;83(11-12):761-7 [18058365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19861-6 [18077419.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):43-52 [14965266.001]
  • (PMID = 18533806.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089720; United States / NCI NIH HHS / CA / R01 CA-89720; United States / NCI NIH HHS / CA / R01 CA109874; United States / NCI NIH HHS / CA / R01 CA109874-04; United States / NCI NIH HHS / CA / R01 CA089720-05; United States / NCI NIH HHS / CA / CA089720-04; United States / NCI NIH HHS / CA / CA089720-05; United States / NCI NIH HHS / CA / R56 CA089720; United States / NCI NIH HHS / CA / R01 CA089720-04; United States / NCI NIH HHS / CA / R01 CA-109874; United States / NCI NIH HHS / CA / CA109874-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 40
  • [Other-IDs] NLM/ NIHMS128881; NLM/ PMC2764989
  •  go-up   go-down


55. Dionigi G, Uccella S, Gandolfo M, Lai A, Bertocchi V, Rovera F, Tanda ML: Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter. Thyroid Res; 2008;1(1):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter.
  • She had a history of renal clear cell carcinoma of the left kidney, which had been resected 2 years previously.
  • A histological examination revealed a solitary metastasis of a clear cell renal cancer in a diffuse multinodular goiter.
  • The diagnosis can be suspected if the patient has a thyroid tumor and a past history of extrathyroid cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2008 May;55(2):359-64 [18379125.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Thyroid. 2008 Jan;18(1):85-7 [17887930.001]
  • [Cites] World J Surg. 2007 May;31(5):879-87 [17308849.001]
  • [Cites] Eur J Surg Oncol. 2007 Feb;33(1):83-5 [17085008.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):698-701 [16021578.001]
  • [Cites] Ann Surg. 1960 Apr;151:551-61 [13820008.001]
  • [Cites] Cancer. 1956 Mar-Apr;9(2):306-9 [13304848.001]
  • [Cites] Ann Surg. 1964 Aug;160:169-77 [14209716.001]
  • [Cites] Cancer. 1962 May-Jun;15:557-65 [13911946.001]
  • [Cites] AMA Arch Pathol. 1955 Mar;59(3):291-311 [14349472.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Thyroid. 1998 Feb;8(2):149-53 [9510123.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):294-301 [9495201.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jan;122(1):37-41 [9448014.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Ann Surg Oncol. 1995 May;2(3):252-6 [7641022.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):637-48 [2261909.001]
  • [Cites] Cancer. 1989 May 1;63(9):1810-5 [2649228.001]
  • [Cites] Tumori. 1987 Apr 30;73(2):187-90 [3554676.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):856-9 [6503368.001]
  • [Cites] Pathol Res Pract. 1985 May;179(6):666-72 [4022843.001]
  • [Cites] Surg Gynecol Obstet. 1982 Oct;155(4):503-5 [7123465.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1487-91 [7272969.001]
  • [Cites] Acta Otolaryngol. 1969 May;67(5):552-62 [5378598.001]
  • [Cites] J Pathol. 1974 May;113(1):21-5 [4412457.001]
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Thyroid. 2004 Jan;14(1):65-70 [15009916.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1869-78 [12404280.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):551-6 [12354139.001]
  • [Cites] Surg Today. 2002;32(2):151-4 [11998944.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2008 Apr;16(2):158-62 [18327036.001]
  • (PMID = 19014412.001).
  • [ISSN] 1756-6614
  • [Journal-full-title] Thyroid research
  • [ISO-abbreviation] Thyroid Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2596782
  •  go-up   go-down


56. Verhoest G, Manunta A, Bensalah K, Vincendeau S, Rioux-Leclercq N, Guillé F, Patard JJ: Laparoscopic partial nephrectomy with clamping of the renal parenchyma: initial experience. Eur Urol; 2007 Nov;52(5):1340-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Final pathologic examination revealed clear cell carcinoma in three cases and angiomyolipoma and oncocytoma in one case each.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Hemostasis, Endoscopic / methods. Kidney Neoplasms / surgery. Laparoscopy / methods. Nephrectomy / methods. Reperfusion Injury / prevention & control

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Nov;52(5):1303-5 [17566640.001]
  • (PMID = 17498865.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


57. Dlova NC: Photo capsules. Skinmed; 2006 May-Jun;5(3):147
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Neoplasms, Unknown Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687986.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Goto K, Takeuchi Y, Yakihara A, Kotsuji F: Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status. Gynecol Oncol; 2005 Jun;97(3):976-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous invasive squamous cell carcinoma and clear cell adenocarcinoma of the uterine cervix: a different human papillomavirus status.
  • BACKGROUND: A multiple primary invasive carcinoma of the cervix is a rare condition and is seldom composed of squamous cell carcinoma and clear cell adenocarcinoma.
  • Preoperative pathological and imaging studies demonstrated the squamous cell carcinoma of the exocervix alone.
  • Radical hysterectomy was performed on the diagnosis of stage 1B cervical cancer.
  • Histological examination of the specimen manifested a coexisting invasive clear cell adenocarcinoma in the endocervix.
  • Human papillomavirus (HPV) 18 was detected in the squamous cell carcinoma; however, no HPV was detected in the clear cell adenocarcinoma.
  • CONCLUSION: This finding suggests that there was an obvious difference in association of HPV with the two neoplasms.
  • [MeSH-major] Adenocarcinoma, Clear Cell / virology. Carcinoma, Squamous Cell / virology. Neoplasms, Multiple Primary / virology. Papillomaviridae. Uterine Cervical Neoplasms / virology


59. Leroy X, Farine MO, Buob D, Wacrenier A, Copin MC: Diagnostic value of cytokeratin 7, CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma. Histopathology; 2007 Dec;51(6):874-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of cytokeratin 7, CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Keratin-7 / metabolism. Membrane Glycoproteins / metabolism. Neprilysin / metabolism


60. Brown AK, Gillis S, Deuel C, Angel C, Glantz C, Dubeshter B: Abnormal cervical cytology: a risk factor for endometrial cancer recurrence. Int J Gynecol Cancer; 2005 May-Jun;15(3):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate the relationship between cervical cytology, histologic type, and risk of endometrial cancer recurrence.
  • We performed a retrospective study of patients undergoing surgery for endometrial carcinoma.
  • Papillary serous and clear cell carcinomas were considered high-risk histologies.
  • For endometrioid adenocarcinoma, abnormal cervical cytology occurred in 61% and 7% recurred, while with high-risk histologies, 84% had abnormal cervical cytology and 19% recurred (P < 0.05).
  • [MeSH-major] Carcinoma / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local. Papanicolaou Test. Vaginal Smears


61. Achach T, Rammeh S, Trabelsi A, Ltaief R, Ben Abdelkrim S, Mokni M, Korbi S: Clear cell adenocarcinoma arising from abdominal wall endometriosis. J Oncol; 2008;2008:478325
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma arising from abdominal wall endometriosis.
  • Histological examination showed a clear cell adenocarcinoma associated with endometriosis foci.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynaecol Obstet. 2005 Sep;90(3):218-22 [16040035.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):432-5 [16445672.001]
  • [Cites] Hum Reprod. 2006 May;21(5):1237-42 [16431901.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):895-9 [16681780.001]
  • [Cites] Int J Gynecol Cancer. 2007 May-Jun;17(3):709-14 [17300680.001]
  • [Cites] BJOG. 2001 Oct;108(10):1106-7 [11702846.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]
  • [Cites] Reproduction. 2004 Mar;127(3):293-304 [15016949.001]
  • [Cites] Histopathology. 1997 Mar;30(3):249-55 [9088954.001]
  • [Cites] J Clin Pathol. 2001 Jan;54(1):76-7 [11271795.001]
  • (PMID = 19266089.001).
  • [ISSN] 1687-8450
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2648644
  •  go-up   go-down


62. Shuch B, La Rochelle JC, Wu J, Klatte T, Riggs SB, Kabbinavar F, Belldegrun AS, Pantuck AJ: Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer; 2008 Sep 15;113(6):1324-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients who underwent CN for renal cell carcinoma (RCC) between 1989 and 2006 were identified.
  • The median disease-specific survival for patients who had an ECOG PS of 0, 1, and 2/3 was 27 months, 13.8 months, and 6.6 months, respectively (P<.001).
  • Patients who had an ECOG PS of 2/3 could be stratified further by the presence or absence of BM into 2 groups (median disease-specific survival: 17.7 months and 2.1 months, respectively; P = .006).
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Nephrectomy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Clear Cell / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [CommentIn] Cancer. 2008 Sep 15;113(6):1282-3 [18661508.001]
  • (PMID = 18661529.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Kim DJ, Lee MH, Park TI, Bae HI: Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. J Korean Med Sci; 2006 Feb;21(1):81-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cases consisted of 33 cases, which included 13 serous cystadenocarcinomas, 1 borderline serous tumor, 8 mucinous cystadenocarcinomas, 6 borderline mucinous tumors and 5 clear cell carcinomas.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 1996;14(5):347-52 [8912475.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1643-7 [10362788.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2048-55 [15583695.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Biol Reprod. 2000 Jun;62(6):1600-9 [10819761.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):242-50 [10861500.001]
  • [Cites] Leuk Res. 2001 Jul;25(7):571-6 [11377682.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Hum Pathol. 2002 May;33(5):484-95 [12094373.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):758-64 [12910520.001]
  • [Cites] Oncologist. 2003;8(6):531-8 [14657531.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):594-7 [15033665.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2416-9 [1707753.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3049-53 [7514496.001]
  • [Cites] Br J Cancer. 1996 May;73(10):1233-6 [8630284.001]
  • [Cites] Hum Pathol. 2005 Mar;36(3):242-9 [15791568.001]
  • (PMID = 16479070.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2733984
  •  go-up   go-down


64. Epstein JI: Precursor lesions to prostatic adenocarcinoma. Virchows Arch; 2009 Jan;454(1):1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor lesions to prostatic adenocarcinoma.
  • High-grade prostatic intraepithelial neoplasia (PIN) is the one well-documented precursor to adenocarcinoma of the prostate.
  • Benign lesions that may be confused with high-grade PIN, including central zone histology, clear cell cribriform hyperplasia, and basal cell hyperplasia are described and illustrated.
  • High-grade PIN is also differentiated from invasive acinar (usual) and ductal adenocarcinoma.
  • The incidence of high-grade PIN, its relationship to carcinoma (including molecular findings), and risk of cancer on rebiopsy are covered in detail.
  • Finally, intraductal carcinoma of the prostate, a controversial entity, is discussed and differentiated from high-grade PIN.
  • [MeSH-major] Adenocarcinoma / pathology. Precancerous Conditions / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Intraepithelial Neoplasia / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):840-8 [9669346.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):437-9 [16567473.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):929-33; discussion 933 [16469583.001]
  • [Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]
  • [Cites] Urology. 1997 Apr;49(4):558-63 [9111625.001]
  • [Cites] Eur Urol. 1999;35(5-6):474-8 [10325508.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1534-9 [11717544.001]
  • [Cites] J Urol. 2006 Jan;175(1):121-4 [16406886.001]
  • [Cites] BJU Int. 2003 Mar;91(4):350-4 [12603413.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):140-4 [10632499.001]
  • [Cites] Urology. 2004 Mar;63(3):503-8 [15028446.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):808-11 [9399656.001]
  • [Cites] BJU Int. 2007 Apr;99(4):765-9 [17378840.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):389-96 [2469333.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):292-7 [16613324.001]
  • [Cites] Prostate. 2000 Apr 1;43(1):11-9 [10725861.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(1):20-31 [17909565.001]
  • [Cites] Hum Pathol. 2002 May;33(5):518-23 [12094377.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):629-33 [15105651.001]
  • [Cites] Cancer. 1969 Jan;23(1):24-34 [5763258.001]
  • [Cites] In Vivo. 1994 May-Jun;8(3):439-43 [7803731.001]
  • [Cites] Urology. 2006 Oct;68(4):800-3 [17070356.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):111-9 [2416422.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):645-59 [7686348.001]
  • [Cites] Urology. 2007 Dec;70(6):1100-3 [18158026.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1291-6 [11283929.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):742-51 [8832557.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]
  • [Cites] J Urol. 2000 Mar;163(3):819-23 [10687984.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):873-86 [7611534.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1184-8 [16931964.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] Prostate. 2000 Sep 1;44(4):265-70 [10951489.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):389-95 [11331955.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):665-71 [3766845.001]
  • [Cites] Cancer Lett. 1999 Jul 1;141(1-2):173-8 [10454259.001]
  • [Cites] Am J Surg Pathol. 2008 Jul;32(7):1060-7 [18496142.001]
  • [Cites] J Urol. 1997 Jul;158(1):12-22 [9186314.001]
  • [Cites] Hum Pathol. 2005 May;36(5):480-5 [15948114.001]
  • [Cites] Am J Surg Pathol. 1996 Jul;20(7):802-14 [8669528.001]
  • [Cites] BJU Int. 2007 Apr;99(4):770-4 [17233800.001]
  • [Cites] BJU Int. 2004 Sep;94(4):528-33 [15329106.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1415-8 [12352407.001]
  • [Cites] Urology. 2005 Apr;65(4):745-9 [15833520.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1215-22 [9331295.001]
  • [Cites] Urology. 1997 Sep;50(3):355-9 [9301697.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1008-13 [15297968.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):435-40 [9130990.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):899-906 [16607376.001]
  • [Cites] Cancer. 1986 Oct 15;58(8):1714-9 [3756794.001]
  • [Cites] Urology. 2001 Dec;58(6):999-1003 [11744476.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] J Urol. 2008 May;179(5):1751-5; discussion 1755 [18343427.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2617-22 [18451224.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):267-74 [15586249.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1528-35 [16980940.001]
  • [Cites] J Urol. 2001 May;165(5):1409-14 [11342887.001]
  • [Cites] Prostate. 1996 Aug;29(2):117-34 [8700801.001]
  • [Cites] Neoplasia. 2006 Oct;8(10 ):826-32 [17032499.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1205-14 [1281386.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1079-85 [11474294.001]
  • [Cites] Int Urol Nephrol. 2007;39(1):189-95 [16835725.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3966-71 [8508361.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1390-4; discussion 1394; author reply 1394 [16145444.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):820-34 [16469560.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):147-55 [11176063.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Can J Urol. 2006 Oct;13(5):3255-60 [17076947.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1119-23 [9781651.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • (PMID = 19048290.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 85
  •  go-up   go-down


65. Puntambekar SP, Patil A, Joshi SN, Rayate NV, Puntambekar SS, Agarwal GA: Preservation of autonomic nerves in laparoscopic total radical hysterectomy. J Laparoendosc Adv Surg Tech A; 2010 Dec;20(10):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with cervical carcinoma of stage Ia2 and Ib1 underwent laparoscopic NSRH along with pelvic lymphadenectomy.
  • Mean operative time was 160 minutes and all 7 patients had clear surgical margins.
  • CONCLUSION: Understanding this technique and the knowledge of laparoscopic anatomy of pelvic autonomic nerves is important in both benign and malignant pelvic surgeries.
  • [MeSH-major] Adenocarcinoma / surgery. Autonomic Pathways. Carcinoma, Squamous Cell / surgery. Hysterectomy. Laparoscopy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091224.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Nur S, Chuang L, Ramaswamy G: Immunohistochemical characterization of cancer antigen in uterine cancers. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1903-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pattern of cancer antigen (CA-125) expression by immunohistochemistry (IHC) was investigated in malignant and nonneoplastic endometrium in endometrial carcinoma.
  • Ninety cases of primary uterine carcinomas (65 endometrioid [EM] carcinoma, 15 serous papillary [SP] carcinoma, 6 carcinosarcomas [malignant mixed müllerian tumors], and 4 clear cell carcinoma [CC]) and adjacent atrophic and/or hyperplastic endometrium were analyzed by IHC for CA-125 expression.
  • The immunoreaction score (IRS score) was calculated and correlated with the grade and stage of carcinoma according to the histologic type.
  • CA-125 expression (3-4/4) was localized in apical borders of grade 1 and grade 2 EM carcinoma and was weak or negative (0-1/4) in grade 3 EM.
  • SP carcinoma and endometrial intraepithelial carcinoma showed much higher mean IRS score than EM.
  • In malignant mixed müllerian tumors (MMMT), the epithelial component stained as above according to the type of epithelial cell differentiation of the neoplastic cells.
  • IRS score correlated with the grade but not with the stage of EM carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. CA-125 Antigen / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Mixed Tumor, Mullerian / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009990.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


67. Rust MM, Susa J, Naylor R, Cavuoti D: Clear cell carcinoma in a background of endometriosis. Case report of a finding in a midline abdominal scar 5 years after a total abdominal hysterectomy. Acta Cytol; 2008 Jul-Aug;52(4):475-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma in a background of endometriosis. Case report of a finding in a midline abdominal scar 5 years after a total abdominal hysterectomy.
  • BACKGROUND: Endometriosis is considered a premalignant process whose association with carcinoma is well documented.
  • We discuss a case of clear cell carcinoma with an unusual presentation in that it was located outside the abdominal cavity and was the only lesion noted clinically and radiologically.
  • The histopathologic diagnostic criteria will be reviewed, as will the association of carcinomas with endometriosis.
  • Furthermore, we will review the current literature of extraovarian clear cell carcinoma associated with endometriosis with regard to clinical outcome.
  • The FNA sample was reported as highly atypical cells suspicious for adenocarcinoma.
  • Excision of this mass revealed a clear cell carcinoma in a background of endometriosis.
  • CONCLUSION: Clear cell carcinoma is one of the most prevalent carcinomas associated with endometriosis, whether identified in the ovary or extraovarian site.
  • [MeSH-major] Abdominal Wall / pathology. Carcinoma / etiology. Cicatrix / pathology. Endometriosis / complications. Hysterectomy / adverse effects. Soft Tissue Neoplasms / etiology


68. Suhail M: Na, K-ATPase: Ubiquitous Multifunctional Transmembrane Protein and its Relevance to Various Pathophysiological Conditions. J Clin Med Res; 2010 Feb;2(1):1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Na(+), K(+)-ATPase (NKA) is an ubiquitous enzyme consisting of α, β and γ subunits, and is responsible for the creation and maintenance of the Na(+) and K(+) gradients across the cell membrane by transporting 3 Na(+) out and 2 K(+) into the cell.
  • Identification of naturally occurring regulators of  NKA could initiate the discovery of new hormone-like control systems involved in the etiology of selected disease processes, hence the importance of understanding the relation of the sodium pump and its ligands to disease.
  • NKA is also involved in hypertension, salt balance, cardiovascular and renal disorders, sperm capacitation, cell volume regulation, apoptosis, rheumatoid arthritis, sepsis, neurological disorders, lung edema clearance and preeclampsia.
  • NKA enzyme activity and subunit levels are reduced in carcinoma, NKA-β levels were highly reduced in an invasive form of human renal clear cell carcinoma, androgen-dependent prostate cancer, in early stages of urothelial cancer, as well as in poorly differentiated, highly motile carcinoma cell lines obtained from various tissues suggesting a functional link between reduced NKA-β expression and cancer progression.
  • It could be a target for the development of anticancer drugs as it serves as a signal transducer, it is a player in cell adhesion and its aberrant expression and activity are implicated in the development and progression of different cancers.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22457695.001).
  • [ISSN] 1918-3003
  • [Journal-full-title] Journal of clinical medicine research
  • [ISO-abbreviation] J Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3299169
  •  go-up   go-down


69. Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M: Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol; 2009 May;22(5):709-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung.
  • Lung cancer classification in small-cell and non-small-cell types was recently challenged by data on the differential efficacy of new cytotoxic agents in specific histotypes.
  • An accurate histotype definition has therefore gained interest in both preoperative and surgical materials, but is a hard task especially in undifferentiated large-cell tumors lacking morphological signs of squamous or glandular differentiation.
  • The responsiveness of these latter subtypes to new drugs apparently more selective for adenocarcinomas or squamous carcinomas is not fully understood, also due to the heterogeneity of diagnostic criteria for this tumor entity.
  • On the basis of gene expression profiling data, reporting a remarkable differential expression of desmocollin-3 (a protein localized in desmosomal junctions of stratified epithelial) between adeno- and squamous cancers, we immunostained 62 cases of resected undifferentiated large-cell lung carcinomas for desmocollin-3 (and for TTF-1, p63 and mucin stain), to test its ability to identify a (residual) squamous phenotype, if present.
  • Desmocollin-3 was expressed in almost half of the undifferentiated large-cell cancers and was mutually exclusive with TTF-1 (positive in 39%; the remaining 18 % of cases was double negative).
  • Special large-cell carcinoma variants expressed desmocollin-3 in 6 of 6 basaloid, 7 of 12 clear-cell types, again mutually exclusive with TTF-1 expression.
  • None of seven sarcomatoid carcinomas reacted for either marker.
  • In 31 cytological samples diagnosed as 'non-small-cell lung carcinoma', desmocollin-3 was again mutually exclusive with TTF-1 and stained all squamous carcinomas, 1 of 19 adenocarcinoma only, and 50% of large-cell carcinoma (all histologically confirmed).
  • This combined morphophenotypic approach may represent a valid adjunct (for both surgical and cytological samples) in the selection of patients with lung cancer to medical treatments tailored according to different efficacy in different lung carcinomas of the squamous, adeno- and large-cell types.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Desmocollins / biosynthesis. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287461.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / DSC3 protein, human; 0 / Desmocollins; 0 / TTF1 protein, human
  •  go-up   go-down


70. Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA: Cancer risk in DES daughters. Cancer Causes Control; 2010 Jul;21(7):999-1007
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk of clear cell adenocarcinoma of the vagina and cervix (CCA) was statistically significantly increased (SIR = 24.23; 95% CI = 8.89, 52.74); the elevated risk persisted above 40 years of age.
  • [MeSH-major] Adenocarcinoma, Clear Cell / epidemiology. Diethylstilbestrol / adverse effects. Nuclear Family. Vaginal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jun 15;342(24):1838-9 [10866558.001]
  • [Cites] Cancer Causes Control. 2008 Jun;19(5):437-42 [18197460.001]
  • [Cites] Hum Reprod. 2001 Nov;16(11):2451-8 [11679537.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):837-45 [11714112.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1681-91 [12711744.001]
  • [Cites] Reprod Toxicol. 2004 Nov;19(1):43-51 [15336711.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] Cancer. 1973 Mar;31(3):573-7 [4693585.001]
  • [Cites] Med Clin North Am. 1974 Jul;58(4):793-810 [4276416.001]
  • [Cites] Fertil Steril. 1987 Aug;48(2):193-7 [3609331.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Fertil Steril. 1988 Jun;49(6):1080-2 [3371486.001]
  • [Cites] Lancet. 1990 Apr 21;335(8695):939-40 [1970028.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2215-20 [2224777.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):5-9 [8202106.001]
  • [Cites] Ann Intern Med. 1995 May 15;122(10):778-88 [7717601.001]
  • [Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:83-7 [8593881.001]
  • [Cites] JAMA. 1998 Aug 19;280(7):630-4 [9718055.001]
  • [Cites] Cancer Causes Control. 2006 Feb;17(1):11-9 [16411048.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S11-7 [16690809.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1509-14 [16896041.001]
  • [Cites] Cell Oncol. 2007;29(1):19-24 [17429138.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):356-60 [17390375.001]
  • [Cites] Am J Obstet Gynecol. 2001 Jul;185(1):78-81 [11483908.001]
  • (PMID = 20204493.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2883094
  •  go-up   go-down


71. Guo WJ, Chen TS, Wang XP, Chen R: Taxol induces concentration-dependent apoptotic and paraptosis-like cell death in human lung adenocarcinoma (ASTC-a-1) cells. J Xray Sci Technol; 2010;18(3):293-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taxol induces concentration-dependent apoptotic and paraptosis-like cell death in human lung adenocarcinoma (ASTC-a-1) cells.
  • Taxol (Paclitaxel) is an important natural product for the treatment of solid tumors such as ovarian, breast, non-small-cell lung tumors, and some head and neck carcinomas.
  • Different concentrations of taxol trigger distinct effects on cell death forms.
  • In present study, cell counting kit (CCK-8) assay, confocal fluorescence microscopy imaging, flow cytometry (FCM) and western blotting (WB) analysis were used to analyze the characteristics of cell death induced by low (35 nM) and high (70 microM) concentration of taxol respectively in human lung adenocarcinoma (ASTC-a-1) cells.
  • Our results showed that low concentration of taxol induced cell death dominantly in apoptotic fashion associated with nuclear fragmentation, protein synthesis, phosphatidylserine (PS) externalization, G2/M cell cycle arrest, Bax translocation into mitochondria and caspase-3 activation, whereas high concentration of this drug induced significant cytoplasm vacuolization, mitochondria swelling and paraptosis-like cell death form without protein synthesis that is necessary for paraptosis.
  • Although the mechanism of high concentration of taxol-induced paraptosis-like cell death has not been clear, this finding might have a potential implication for cancer therapy, especially for apoptosis-resistant cancer.
  • [MeSH-minor] Adenocarcinoma / metabolism. Annexins / metabolism. Blotting, Western. Caspase 3 / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival. Cytoplasm / metabolism. Dose-Response Relationship, Drug. Flow Cytometry. Humans. Lung Neoplasms / metabolism. Membrane Potential, Mitochondrial / drug effects. Microscopy, Confocal. Microscopy, Fluorescence. Vacuoles / metabolism. bcl-2-Associated X Protein / metabolism

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714087.001).
  • [ISSN] 1095-9114
  • [Journal-full-title] Journal of X-ray science and technology
  • [ISO-abbreviation] J Xray Sci Technol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Annexins; 0 / BAX protein, human; 0 / bcl-2-Associated X Protein; EC 3.4.22.- / Caspase 3; P88XT4IS4D / Paclitaxel; Adenocarcinoma of lung
  •  go-up   go-down


72. Takakura S, Saito M, Ueda K, Motegi M, Takao M, Yamada K, Okamoto A, Niimi S, Sasaki H, Tanaka T, Ochiai K: Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma. Int Surg; 2007 Jul-Aug;92(4):202-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
  • Patients with ovarian clear cell adenocarcinoma (OCCA) show a poor response to conventional platinum-based chemotherapy.
  • Two complete responses (CRs) were obtained in the three patients with measurable disease, and response duration was 7 and 15 months, respectively.
  • One patient had stable disease (SD), and the time to progression was 5 months.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Infusions, Intravenous. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050828.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


73. Dacic S: EGFR assays in lung cancer. Adv Anat Pathol; 2008 Jul;15(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was clear from the experience with targeted therapy for breast cancer that a new standardized assay procedure for assessing and predicting the effects of therapeutic agents must be developed.
  • This observation revolutionized understanding of EGFR in lung carcinogenesis and resulted in numerous retrospective studies that correlated patient's response and molecular profile of the lung adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Humans. In Situ Hybridization, Fluorescence. Polymerase Chain Reaction. Prognosis


74. Kawaguchi M, Watanabe J, Hamano M, Kamata Y, Arai T, Nishimura Y, Obokata A, Jobo T, Kuramoto H: Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA. Eur J Gynaecol Oncol; 2006;27(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medroxyprogesterone acetate stimulates cdk inhibitors, p21 and p27, in endometrial carcinoma cells transfected with progesterone receptor-B cDNA.
  • PURPOSE OF INVESTIGATION: Progestin is reported to suppress the growth of endometrial carcinomas, although its precise mechanism of action is not clear.
  • This study aimed to transfect progesterone receptor-B (PRB) cDNA into endometrial carcinoma cells and investigate the effect of medroxyprogesterone acetate (MPA) on cell growth, and p21 and p27 expression in the transfectant.
  • CONCLUSION: p21 and p27 may be related to progesterone-induced growth suppression in human endometrial adenocarcinoma.
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. DNA, Complementary / analysis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Sampling Studies. Sensitivity and Specificity. Transfection

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550965.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA, Complementary; 0 / Receptors, Progesterone; 0 / progesterone receptor B; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


75. Han G, Gilks CB, Leung S, Ewanowich CA, Irving JA, Longacre TA, Soslow RA: Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol; 2008 Jul;32(7):955-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
  • There are conflicting data about chemoresistance and prognosis in ovarian clear cell carcinoma (CCC).
  • This could be due to significant interobserver variation in the diagnosis of CCC and other ovarian surface epithelial tumors containing clear cells.
  • Thirty-two cases previously diagnosed as CCC, high-grade ovarian serous carcinoma (SC), and mixed surface epithelial carcinoma (SEC) with clear cell and serous components were reviewed by 4 gynecologic pathologists blinded to the original diagnoses.
  • Immunoreactivities of the mixed SECs were similar to those of pure SC, but significantly different from those of pure CCC for Wilm tumor 1 (P=0.0011 for both components), estrogen receptor (P=0.0003 for clear cell component, P=0.0001 for serous component), and p53 (P=0.0062 for both components).
  • The serous and clear cell components of mixed SEC showed higher mitotic rates than pure CCC (P=0.004 and P=0.023, respectively), but the mitotic rate of pure SC was similar to the mixed SEC.
  • We conclude that (1) pure CCC is reproducibly diagnosed. (2) The diagnosis of mixed ovarian SEC with clear cell component is not reproducible. (3) Mixed SEC with clear cell and serous components show similar stage, mitotic activities, and immunoreactivities to those of pure SC, and likely represent SC with clear cell changes.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Cystadenocarcinoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460981.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Michal M, Hes O, Nemcova J, Sima R, Kuroda N, Bulimbasic S, Franco M, Sakaida N, Danis D, Kazakov DV, Ohe C, Hora M: Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity. Virchows Arch; 2009 Jan;454(1):89-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity.
  • The tumors were composed of admixture of an epithelial clear cell component and prominent leiomyomatous stroma.
  • All tubular/glandular structures were lined by a fine capillary network.
  • RAT is a distinct morphologic entity, being different morphologically, immunohistochemically, and genetically from all renal tumors including conventional clear cell carcinoma and mixed epithelial and stromal tumor of kidney.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Virchows Arch. 2009 Apr;454(4):479-80 [19205727.001]
  • [Cites] Radiology. 1983 Feb;146(2):309-21 [6294736.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1372-81 [17063076.001]
  • [Cites] Eur Urol. 1987;13(4):276-80 [2820738.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):951-6; discussion 957-9 [8302716.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):377-82 [18300814.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):220-1 [12861412.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):359-67 [15322873.001]
  • [Cites] Pathol Res Pract. 2000;196(4):275-6 [10782473.001]
  • [Cites] Pathol Int. 2005 Mar;55(3):150-4 [15743324.001]
  • [Cites] Ann Diagn Pathol. 1998 Feb;2(1):12-8 [9845718.001]
  • [Cites] Ultrastruct Pathol. 1988 Jan-Feb;12(1):131-6 [3354071.001]
  • [Cites] Ann Diagn Pathol. 2000 Oct;4(5):311-5 [11073338.001]
  • [Cites] Virchows Arch. 2005 Sep;447(3):669-71 [16025280.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):98-100 [17213356.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):203-10 [10680888.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):700-2 [11764393.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):962-6 [15223969.001]
  • [Cites] Br J Urol. 1977 Nov;49(6):441-6 [588942.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1239-45 [18594469.001]
  • [Cites] Pathol Res Pract. 1998;194(6):445-8 [9689654.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):958-70 [10895818.001]
  • (PMID = 19020896.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein; EC 6.3.2.- / VHL protein, human
  •  go-up   go-down


77. Kusumoto T, Kodama J, Seki N, Nakamura K, Hongo A, Hiramatsu Y: Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep; 2010 Apr;23(4):917-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proteoglycans are ubiquitous components of the extracellular matrix and cell surface, and may mediate tumor progression and metastasis.
  • Epithelial syndecan-1 expression was significantly lower in patients with advanced disease.
  • Epithelial versican expression was significantly higher in patients with early disease, especially in clear cell adenocarcinoma patients.
  • Stromal syndecan-1 and versican expression was significantly higher in patients with advanced disease.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Syndecan-1 / biosynthesis. Versicans / biosynthesis
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204274.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / VCAN protein, human; 126968-45-4 / Versicans
  •  go-up   go-down


78. Lax SF: Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology; 2007 Feb;39(1):46-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial carcinoma, endometrial stromal tumours and mixed malignant mesodermal tumours (MMMT) develop along distinctive molecular genetic pathways.
  • Two distinctive types of endometrial carcinoma are distinguished, type I and type II, which develop along distinctive pathways and show different clinical behaviour and histological features.
  • Type I carcinomas show endometrioid histology, are oestrogen-related and develop from atypical endometrial hyperplasia.
  • The molecular tumorigenesis is comparable to colorectal carcinoma with a step-like progression and an accumulation of genetic alterations.
  • Alterations of PTEN, K-Ras mutations and microsatellite instability are frequent and early events in type I carcinoma, whereas p53 mutations occur during progression to grade 3 carcinoma.
  • Serous and clear cell carcinomas are considered type II carcinomas which are mostly unrelated to oestrogen. p53 mutations occur in almost all serous carcinomas and seem to occur early, leading to massive chromosomal instability and rapid tumour progression.
  • Gene expression profiling has supported this dualistic model of endometrial carcinoma.
  • There is evidence of molecular differences between serous and clear cell carcinomas as well as between endometrioid carcinomas with and without microsatellite instability.
  • Endometrial stromal sarcomas (ESS; type I endometrial sarcoma) are oestrogen-related and seem to develop from endometrial stromal nodules (ESN).
  • They are histologically and genetically distinct from undifferentiated endometrial sarcoma (UES) which seem to be mostly unrelated to oestrogen (type II endometrial sarcoma).
  • In MMMT, which is considered a metaplastic carcinoma, p53 alteration occurs early, before clonal expansion and acquisition of genetic diversity during progression.
  • [MeSH-major] Endometrial Neoplasms / genetics. Endometrial Stromal Tumors / genetics. Molecular Biology. Neoplasms, Glandular and Epithelial / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365822.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 82
  •  go-up   go-down


79. Soda T, Nishimura K, Kobayashi Y, Kato T, Tokugawa S, Kishikawa H, Ihara H, Ichikawa Y: [A case of synchronous contralateral renal cell carcinoma and urothelial carcinoma]. Hinyokika Kiyo; 2009 Aug;55(8):491-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous contralateral renal cell carcinoma and urothelial carcinoma].
  • Histological examination findings showed that the right renal tumor was a renal cell carcinoma, clear cell type, G1, INFalpha, pT2, ly0, v0, and that the splenic tumor was an arteriovenous fistula.
  • Next, transurethral resection of the bladder tumor was performed and a histological examination showed urothelial carcinoma.
  • Left total nephroureterectomy and cystectomy were performed, and the histological diagnosis was urothelial carcinoma, G3, pT3, ly1, v2.
  • It is rare for a renal cell carcinoma and contralateral renal pelvic cancer to occur simultaneously, as only 15 cases including the present have been reported in Japan.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764535.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


80. Takami M, Kita E, Kuwana Y, Ohta Y, Nakayama Y, Fukai H, Matsumoto H, Takimoto T, Ichikawa G, Yamamoto T: [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1243-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
  • Clear-cell carcinoma of the ovary is a highly malignant neoplasm.
  • Survival of patients in the advanced stage is poor, and the best treatment is not clear.
  • We report here a case of a 57-year-old woman who had Stage IIIb advanced clearcell carcinoma of the ovary.
  • Considering the poor prognosis of clear-cell carcinoma, this regimen is thought to be effective for advanced clear-cell carcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633273.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


81. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res; 2009 Sep 1;15(17):5404-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
  • PURPOSE: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer.
  • This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype.
  • EXPERIMENTAL DESIGN: Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the expression of phospho-mTOR was assessed by immunohistochemistry.
  • Then, the growth-inhibitory effect of mTOR inhibition by RAD001 (everolimus) was examined using two pairs of cisplatin-sensitive parental (RMG1 and KOC7C) and cisplatin-resistant human clear cell carcinoma cell lines (RMG1-CR and KOC7C-CR) both in vitro and in vivo.
  • RESULTS: Immunohistochemical analysis showed that mTOR was more frequently activated in clear cell carcinomas than in serous adenocarcinomas (86.6% versus 50%).
  • CONCLUSION: mTOR is frequently activated in clear cell carcinoma and can be a promising therapeutic target in the management of clear cell carcinoma.
  • Moreover, mTOR inhibition by RAD001 may be efficacious as a second-line treatment of recurrent disease in patients previously treated with cisplatin.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):336-44 [18639330.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5853-7 [15208673.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):643-9 [15350353.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5315-22 [9478990.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7418-26 [15534119.001]
  • [Cites] Cell. 2005 Mar 25;120(6):747-59 [15797377.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Mol Cancer Ther. 2005 Oct;4(10):1533-40 [16227402.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6 [16445610.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):71-5 [16290000.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1761-9 [16396982.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):285-91 [16516283.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):138-43 [16847906.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1545-51 [16884363.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2584-9 [10861437.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5988-94 [11085518.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1862-8 [11280739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9 [11504908.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2448-54 [12114452.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33490-500 [12087097.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1491-501 [12820963.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):123-9 [14529671.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):252-61 [14729632.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1013-23 [14871980.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Oncogene. 2007 Mar 22;26(13):1932-40 [17001314.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):404-8 [17292461.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4261-70 [17634556.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Autophagy. 2008 May;4(4):467-75 [18259115.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):197-203 [15262142.001]
  • (PMID = 19690197.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA06927; United States / NCI NIH HHS / CA / CA083638-10; United States / NCI NIH HHS / CA / CA077429-02; United States / NCI NIH HHS / CA / P30 CA006927-45; United States / NCI NIH HHS / CA / CA83638; United States / NCI NIH HHS / CA / R01 CA077429; United States / NCI NIH HHS / CA / P50 CA083638-10; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / R01 CA077429-02; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS125079; NLM/ PMC2743856
  •  go-up   go-down


82. Sullivan LM, Smolkin ME, Frierson HF Jr, Galgano MT: Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology. Am J Surg Pathol; 2008 Nov;32(11):1608-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.
  • In addition to staining adenocarcinomas of the alimentary system, studies have demonstrated CDX2 positivity in a percentage of ovarian mucinous and endometrioid tumors, carcinoids, and some adenocarcinomas of other sites such as the urinary bladder, prostate, lung, and pancreas.
  • However, CDX2 immunostaining in cervical adenocarcinomas has not been examined in detail with comparison to important clinicopathologic characteristics including histopathologic subtype, tumor stage, and patient follow-up.
  • In this study of 81 invasive cervical adenocarcinomas, 24 of the cases (30%) demonstrated nuclear positivity.
  • Ten of the 15 (67%) endometrioid tumors had positive nuclear staining, compared with 7 of the 33 (21%) endocervical "usual-type" carcinomas, and 7 of the 33 (21%) remaining subtypes (adenosquamous, glassy cell, clear cell, serous, villoglandular, enteric).
  • Positive nuclear or cytoplasmic staining for CDX2 did not correlate with disease stage or patient outcome.
  • Our results indicate that cervical adenocarcinomas can show nuclear immunopositivity for CDX2 even in the absence of overt morphologic features of colorectal differentiation.
  • The frequency and pattern of CDX2 staining in the more common histologic subtypes of cervical adenocarcinoma (endocervical usual-type and endometrioid) is parallel to that which is seen for adenocarcinomas of the upper gastrointestinal tract and pancreaticobiliary system.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Intestine, Large / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753946.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


83. Sakurai H, Okamoto M, Hasegawa M, Satoh T, Oikawa M, Kamiya T, Arakawa K, Nakano T: Direct visualization and quantification of the anticancer agent, cis-diamminedichloro-platinum(II), in human lung cancer cells using in-air microparticle-induced X-ray emission analysis. Cancer Sci; 2008 May;99(5):901-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This system was used to develop an imaging and quantification method for intracellular cis-diamminedichloro-platinum(II) (CDDP) in a human lung cancer cell line.
  • A human lung adenocarcinoma cell line, A549, was cultured and nuclear labeling was carried out by incubating the cells with BrdU.
  • No clear platinum signal was detected after exposure to CDDP for 24 h at doses between 1 and 100 micromol.
  • When nucleus and cytoplasm visualization was sufficiently clear to efficiently use in-air micro-PIXE, the platinum image quality was considered satisfactory.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294282.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


84. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA: Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol; 2006 Aug;102(2):285-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
  • PURPOSE: Ovarian clear-cell carcinomas (OCCC) are known to be possibly resistant to platinum-based chemotherapy and to have a poorer prognosis with respect to other subtypes of epithelial ovarian cancer (EOC).
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516283.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


85. Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group: Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer; 2008 Jan 1;122(1):170-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Factors potentially linked to ovarian inflammation were examined in an Australia-wide case-control study comprising 1,576 women with invasive and low malignant potential (LMP) ovarian tumours and 1,509 population-based controls.
  • Other factors potentially associated with ovarian inflammation (pelvic inflammatory disease, human papilloma virus infection and mumps) were not associated with risk but, like others, we found an increased risk of endometrioid and clear cell ovarian cancer only among women with a history of endometriosis.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Ovarian Neoplasms / epidemiology. Pelvic Inflammatory Disease / epidemiology. Talc / administration & dosage
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / epidemiology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / epidemiology. Adolescent. Adult. Aged. Aspirin / administration & dosage. Australia / epidemiology. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / epidemiology. Case-Control Studies. Chronic Disease. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Risk Factors


86. Zhang SQ, Wang SL, Wang SM: [One case of metastatic clear cell carcinoma from kidney to maxilla]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Jul;40(7):551
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One case of metastatic clear cell carcinoma from kidney to maxilla].
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Kidney Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200974.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC: Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol; 2009 Oct;4(10):1212-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
  • The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC).
  • RESULTS: Sixteen cases (33%) displayed clear discordance in the EGFR status between the primary tumor and the metastasis, with a significant trend toward downregulation of EGFR in the metastasis (p = 0.01).
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Brain Neoplasms / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Survival Rate. Vascular Endothelial Growth Factor A / metabolism


88. Vlahos NF, Kalampokas T, Fotiou S: Endometriosis and ovarian cancer: a review. Gynecol Endocrinol; 2010 Mar;26(3):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrioid and clear-cell are the most frequent types of ovarian cancer associated with endometriosis.
  • CONCLUSION: There is evidence to support that endometriosis (by definition a benign process), could simultaneously have the potential for malignant transformation.
  • More studies are needed to establish risk factors that may lead to malignant transformation of this condition and to identify predisposed individuals who may require closer surveillance.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Endometriosis. Ovarian Neoplasms

  • Genetic Alliance. consumer health - Endometriosis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19718562.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


89. Briese J, Schulte HM, Bamberger CM, Löning T, Bamberger AM: Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1. Int J Gynecol Pathol; 2006 Apr;25(2):161-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of osteopontin in endometrial carcinoma: correlation with expression of the adhesion molecule CEACAM1.
  • In this study, immunohistochemistry and immunofluorescence with specific antibodies were performed on a series of 20 normal endometrial samples, 17 endometrial hyperplasias, and 43 endometrial carcinomas (28 endometrioid, 10 serous, and 5 clear cell carcinomas) to investigate the expression pattern and cell-type specific localization of OPN and to correlate it with the expression of CEACAM1.
  • Strong OPN expression with a consistent cytoplasmic localization in epithelial glandular cells was observed in the normal human endometrium in 80% of the samples of the proliferative and secretory phase (score 8-12).
  • Strong expression of OPN could be observed in 29 (67.4%) of the 43 analyzed endometrial carcinomas.
  • In endometrioid carcinoma with increasing malignancy grade, increasing areas with low OPN expression level or complete loss of OPN expression could be observed.
  • In this study, the different expression patterns of OPN in endometrial tumors could additionally support the biological diversity of endometrioid and serous carcinomas together with other markers.
  • [MeSH-major] Adenocarcinoma, Scirrhous / chemistry. Antigens, CD / analysis. Carcinoma, Endometrioid / chemistry. Cell Adhesion Molecules / analysis. Endometrial Neoplasms / chemistry. Sialoglycoproteins / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633066.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  •  go-up   go-down


90. Noskova V, Ahmadi S, Asander E, Casslén B: Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol Oncol; 2009 Oct;115(1):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: ES-2 clear cell carcinoma cells were grown in tissue culture inserts in a double-chamber system with fibroblastic stromal LEP cells embedded in Matrigel.
  • Real time PCR measured uPA mRNA in LEP cells, as well as mRNA for cytokines in both cell types.
  • CONCLUSION: We identified two cytokines as paracrine signals, and five cytokines as autocrine signals in ovarian cancer cell induced up-regulation of uPA mRNA in stromal fibroblastic cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Communication / physiology. Fibroblasts / cytology. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis. Stromal Cells / cytology. Urokinase-Type Plasminogen Activator / genetics
  • [MeSH-minor] Cell Line, Tumor. Coculture Techniques. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19631971.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


91. Zheng FF, Dai YP, Luo DS, Liang YY, Deng CH, Chen W, Chen LW, Li XF, Qiu SP, Zheng KL: [Clinical analysis of renal cell carcinoma: report of 271 cases]. Zhonghua Wai Ke Za Zhi; 2008 Jun 1;46(11):829-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of renal cell carcinoma: report of 271 cases].
  • OBJECTIVE: To study the diagnosis and treatment of renal cell carcinoma.
  • METHOD: From January 1993 to December 2000 the data of 271 cases of renal cell carcinoma were reviewed.
  • The pathological results showed that 137 cases (61.4%) were clear cell carcinoma, 18 cases (8.
  • 1%) of granular cell carcinoma, 32 cases (14.
  • 3%) being combination of the above two varieties, 23 cases (10.3%) of renal papillary adenocarcinoma, 13 cases being renal cell of other types.
  • CONCLUSIONS: Ultrasonography is the first select examination method of detecting of renal cell carcinoma, and CT scanning is the most valuable diagnostic mean.
  • Early diagnosis and prompt radical nephrectomy or nephron sparing nephrectomy are the critical points for achieving long-term survivals of patients with renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / diagnosis. Kidney Neoplasms / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035217.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Liu M, Wang JY, Zhang YG, Zhu SC, Lu ZH, Wan B: [Detection of urological and male genital tumors diagnosed in Beijing Hospital 1995 - 2004]. Zhonghua Yi Xue Za Zhi; 2007 Sep 11;87(34):2423-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest malignancies included transitional cell carcinoma of bladder (n = 387), carcinoma of prostate (n = 271), and clear cell carcinoma of kidney (n = 250).
  • The ratio of metastatic carcinoma in prostate and kidney decreased with each passing year.
  • Before 1999 75.48% of the patients with prostate carcinoma visited the hospital because of low urinary tract symptom (LUTS), and only 12.48% because of abnormalities discovered during physical examination, However, after 2000 the percentage of the prostate carcinoma patients who visited the hospital because of LUST deceased to 54.44%, and those because of abnormalities discovered during physical examination increased to 40.99% (P < 0.01).
  • CONCLUSION: The improvement of diagnostic methods has changed the condition of tumor diagnosis in recent years.
  • [MeSH-major] Hospitalization / statistics & numerical data. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. China / epidemiology. Cross-Sectional Studies. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / epidemiology. Male. Middle Aged. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / epidemiology. Retrospective Studies. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036323.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


93. Fijuth J: Brachytherapy in paediatric malignancies - review of indications. J Contemp Brachytherapy; 2010 Jun;2(2):81-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment strategies directed towards the reduction of late side effects have significantly increased interest in brachytherapy, in particular of soft tissue sarcoma and clear cell adenocarcinoma, as in these malignancies often only a limited target volume needs to be treated by a significant radiation dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27829850.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; HDR / LDR / brachytherapy / paediatric malignancies
  •  go-up   go-down


94. Okuda M, Huang CL, Haba R, Yokomise H: Clear cell carcinoma originating from ectopic thymus. Gen Thorac Cardiovasc Surg; 2009 May;57(5):269-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma originating from ectopic thymus.
  • Cancer of the mediastinum is known to be a relatively rare disease, and clear cell carcinoma in the mediastinum is especially rare.
  • Ectopic thymus is not uncommon, but clear cell carcinoma originating from ectopic thymus has never been reported.
  • We report a case of clear cell carcinoma originating from ectopic thymus in which there was a good response to steroid-supplemented chemoradiotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Choristoma / pathology. Mediastinal Neoplasms / pathology. Thymus Gland

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pediatr Otorhinolaryngol. 1999 Jan 25;47(1):29-39 [10206392.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):1025-32 [1991250.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1474-81 [9850173.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 May;131(5):314-22 [15703942.001]
  • [Cites] Am J Otolaryngol. 2001 Jul-Aug;22(4):294-6 [11464329.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1658-9 [17532980.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Feb;107(2):615-20 [8302083.001]
  • [Cites] Histopathology. 2004 Apr;44(4):367-74 [15049903.001]
  • [Cites] Am J Surg Pathol. 1982 Jul;6(5):451-70 [7125053.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):835-41 [7793482.001]
  • (PMID = 19440827.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Ejaz AA, Geiger XJ, Wasiluk A: Focal segmental glomerulosclerosis in kidney resected for renal cell carcinoma. Int Urol Nephrol; 2005;37(2):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal segmental glomerulosclerosis in kidney resected for renal cell carcinoma.
  • A diagnosis of renal dysfunction is usually made on the basis of clinical, biochemical, radiologic, and renal tissue analysis.
  • Accurate diagnosis often requires a renal biopsy, but that procedure is contraindicated in certain clinical circumstances, particularly in patients who have only one kidney.
  • We describe a patient who previously had undergone left nephrectomy for a renal clear cell carcinoma, in whom the diagnosis of focal segmental glomerulosclerosis was made on retrospective analysis of remnant renal tissue from the patient's nephrectomy specimen.
  • [MeSH-major] Carcinoma, Renal Cell / complications. Glomerulosclerosis, Focal Segmental / complications. Kidney Neoplasms / complications


96. Abascal Junquera JM, Cecchini Rosell L, Martos Calvo R, Salvador Lacambra C, Celma Doménech A, De Torres I, Morote Robles J: [Presentation of a new case of primary clear cell adenocarcinoma of the urethra and its surgical management]. Actas Urol Esp; 2007 Apr;31(4):411-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Presentation of a new case of primary clear cell adenocarcinoma of the urethra and its surgical management].
  • [Transliterated title] Presentación de un nuevo caso de adenocarcinoma de células claras uretral y su manejo quirúrgico.
  • OBJECTIVE: To present a new case of a primary clear cell adenocarcinoma of the urethra and its surgical management.
  • MATERIAL AND METHODS: We describe the clinical, diagnosis, treatment and development of this kind of tumor.
  • CONCLUSIONS: It is an unusual type of cancer associated with poor prognosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / surgery. Urethral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633929.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


97. Will TA, Agarwal N, Petruzzelli GJ: Oral cavity metastasis of renal cell carcinoma: a case report. J Med Case Rep; 2008;2:313
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cavity metastasis of renal cell carcinoma: a case report.
  • INTRODUCTION: Despite being reported rarely, renal cell carcinoma is the third most frequent neoplasm to metastasize to the head and neck region preceded only by breast and lung cancer.
  • Little information exists regarding the presentation and work-up of metastatic renal cell carcinoma in the oral cavity.
  • Immunoperoxidase testing was necessary to make the diagnosis of metastatic renal cell carcinoma and rule out other clear cell carcinomas of salivary gland origin.
  • CONCLUSION: Metastatic renal cell carcinoma is part of the differential diagnosis for patients presenting with a new head or neck lesion in the setting of a history of kidney cancer.
  • The physician needs to be prepared for the increased risk of bleeding and understand the importance of immunohistochemical staining to differentiate between metastatic renal cell carcinoma and malignancies of salivary origin.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Case Rep. 2008;2:249 [18657269.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e76-8 [16504856.001]
  • [Cites] Hinyokika Kiyo. 2004 Nov;50(11):791-3 [15628540.001]
  • [Cites] Cardiovasc Intervent Radiol. 1991 Jan-Feb;14(1):50-4 [2044129.001]
  • [Cites] Mich Med. 1971 Jul;70(16):616-8 [5571989.001]
  • [Cites] Urol Oncol. 2004 May-Jun;22(3):214-23; discussion 223-4 [15271320.001]
  • [Cites] Acta Otolaryngol. 2004 Mar;124(2):197-201 [15072424.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Aug;60(8):942-4 [12149744.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • (PMID = 18823541.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2566576
  •  go-up   go-down


98. Hynninen P, Vaskivuo L, Saarnio J, Haapasalo H, Kivelä J, Pastoreková S, Pastorek J, Waheed A, Sly WS, Puistola U, Parkkila S: Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology; 2006 Dec;49(6):594-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In malignant tumours, the staining was most prominent in hypoxic regions.
  • Expression of CA XII was detected in all tumour categories, although the mean staining intensity was weaker than for CA IX in all groups except for clear cell carcinomas.
  • The expression pattern of CA IX suggests that it could also serve as a useful histopathological marker protein for hypoxia in malignant ovarian tumours.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carbonic Anhydrases / metabolism. Cell Membrane / enzymology. Cystadenocarcinoma, Mucinous / enzymology. Cystadenocarcinoma, Serous / enzymology. Cystadenoma, Mucinous / enzymology. Ovarian Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163844.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK40163
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Isoenzymes; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase XII
  •  go-up   go-down


99. Dimova I, Raitcheva S, Dimitrov R, Doganov N, Toncheva D: Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours. Eur J Cancer; 2006 Mar;42(5):674-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established c-myc amplification in more than 30% in endometrioid and mixed epithelial ovarian carcinomas. c-myc gains were found in a high proportion (42.9%) of clear cell carcinomas.
  • We found associations between c-myc copy-number changes and clinicopathological parameters of ovarian tumours such as degree of malignancy and histological type.
  • We suggested that c-myc amplifications are characteristics for endometrioid, and c-myc gains for clear cell ovarian cancers.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458500.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


100. Okada T, Masuda N, Fukai Y, Shimura T, Nishida Y, Hosouchi Y, Kashiwabara K, Nakajima T, Kuwano H: Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas. Anticancer Res; 2006 Jul-Aug;26(4B):3105-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas.
  • BACKGROUND: 14-3-3 sigma (sigma) has been shown to be overexpressed in pancreatic cancers by a c-DNA microarray technique.
  • MATERIALS AND METHODS: To evaluate the biological importance of 14-3-3 sigma expression in pancreatic carcinogenesis, immunohistochemistry for 14-3-3 sigma, CDX2, MUC1, MUC2, p53, p16 and Ki-67 was carried out on 33 IPMTs and the results were compared with those for 14 invasive ductal carcinomas (IDCs).
  • In IPMT, dark columnar cell types prevailed over clear columnar cell types in terms of the frequency of the Ki-67 labeling index.
  • Moreover, IPMT composed of dark columnar cells might be a potentially more advanced form than that made up of clear columnar cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Papillary / metabolism. Exonucleases / biosynthesis. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / metabolism






Advertisement